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Improving Prostate Cancer Detection in Veterans through the Development of a Clinical  
Decision Rule for Prostate Biopsy 
 
Captain Owen T. Hill, PA-C, MPAS 
 
ABSTRACT 
 
In the U.S., the number of prostate biopsies increases annually. This is partly due 
to elevated prostate specific antigen (PSA) values identified during PC screening.  
 This study’s goal was improving prostate cancer (PC) detection through 
developing a clinical decision rule (CDR), based on an elevated PSA and laboratory 
biomarkers. This decision rule could be used after an elevated PSA, providing the patient 
and clinician information to consider prior to biopsy. This cross-sectional study evaluated 
men from the Tampa, Florida, James A. Haley (JH) VA (N=1,378), from January 1, 
1998, through April 15, 2005. 
 The study hypothesized that specific lab biomarkers among JH VA PC cases 
would differ significantly from JH VA patients without PC.  The following biomarkers 
were related to PC: hemoglobin (HGB) (OR=1.42 95%CI 1.27, 1.59); red blood cell 
count (RBC) (OR=2.52 95%CI 1.67, 3.78); PSA (OR=1.04 95%CI 1.03, 1.05); and, 
creatinine (OR=1.55 95%CI 1.12, 2.15).  
This study attempted to determine whether including specific biomarkers (that are 
related to systemic diseases associated with advancing PC) could improve PC prediction 
(versus PSA alone). Comparing all PC stages versus non-cancerous conditions, the 
Receiver Operator Characteristic (ROC) curve area under the curve (AUC) expanded 
 xi 
(increasing the probability of correctly classifying PC): PSA (alone) 0.59 (95% CI 0.55, 
0.61); CDR model 0.68 (95%CI 0.65, 0.71), and the positive predictive value (PPV) 
increased: PSA 44.7%; CDR model 61.8%.  Comparing PC (stages B, C, D) vs. other, the 
ROC AUC increased:  PSA (alone) 0.63 (95% CI 0.58, 0.66); CDR model 0.68 (95% CI 
0.68, 0.75), and the PPV increased: 20.6% (PSA); CDR model 55.3%.  
These results suggest evaluating certain biomarkers might improve PC prediction 
prior to biopsy. Moreover, the biomarkers may be more helpful in detecting clinically 
relevant PC. Follow-up studies should begin with replicating the study on different U.S. 
VA data-sets involving multiple practices. 
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Chapter I: Introduction 
 
           In the United States, the number of men who undergo prostate biopsies to rule out 
prostate cancer (PC) increases annually.1 This is in large part a result of elevated serum 
prostate specific antigen (PSA) values identified during routine screening for prostate 
cancer. Debate over the appropriateness of prostate cancer screening is ongoing.1, 8, 11 In 
addition; there is controversy over the proper course one should take upon detecting PSA 
elevations.8 Moreover, deliberation continues over whether prostate cancer qualifies as a 
disease eligible for screening. Lastly, it is inconclusive whether early prostate cancer 
detection truly results in lower morbidity and mortality for the men identified. 1, 8, 11, 15
Despite the wide spread use of the PSA screening test in the medical community, 
the U.S. Preventive Task Force (an agency that provides medical screening guidance) 
state the following, "routine screening for prostate cancer with digital rectal examination 
(DRE), serum tumor markers (PSA), or transrectal ultrasound (TRUS), is not 
recommended".2  Additionally, the National Cancer Institute, World Health Organization, 
Canadian Cancer Society, and International Union against Cancer do not support the 
routine screening of men for prostate cancer. Conversely, the American Cancer Society, 
American College of Radiology, and the American Urological Association do 
recommend screening men above the age of 50 with a routine PSA serum draw and a 
DRE.16  
   The contrasts in the above recommendations demonstrate the diverse views that 
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exist in the medical community on prostate cancer screening. Proponents’ for routine 
prostate cancer screening argue that screening is a valuable early detection tool because it 
can identify PC in asymptomatic men prior to clinical presentation. Earlier identified PC 
should be at a less advanced stage, which implies a more treatable state. There is 
evidence that supports this claim, demonstrating longer survival in patients with earlier 
identified disease.17 In a 1996 study looking at racial differences in prostate cancer 
screening, a statistically significant stage shift towards less invasive disease was 
discovered when evaluating men who were screened verses those not screened (or who 
had PC recognized by other methods than screening; i.e. clinical identification). Ninety 
percent of prostate cancer identified through screening were localized within the prostate, 
much more than that of clinical identification.17 It is estimated that men who are 
diagnosed with non-palpable tumors (stage A-organ confined) have a survival rate of 87 
percent, while metastatic PC (stage D) survival rates are approximately 30 percent.4 
Additionally, for the majority of cases, type A tumors have lower Grade status 
(determined by the Gleason score), lending themselves to be better candidates for 
curative treatments.16 This data is controversial however, due in part to two major issues. 
The first revolves around the unknown path many of the stage A PC tumors (small and 
prostate confined) can take. Prostate cancer can be very slow growing, and in many cases 
never becoming clinically evident. In a study of PC identified on autopsy, 30 percent of 
men over the age of 50 had histological evidence of prostate cancer.5 In an additional 
study of elderly men and prostate cancer, 57 percent of men over the age of 80 had 
prostate cancer identified by step section biopsy.46 Secondly, categorizing all PC as 
‘prostate cancer’ can be misleading. Not all prostate cancer act in the same fashion. Many 
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prostate cancers are indolent, with a high likelihood of never becoming clinically 
relevant. Conversely, an aggressive PC may rapidly advance from a pre-clinical state to 
invading organs in a metastatic fashion.16   
An essential goal of prostate cancer screening is to identify PC that would 
progress to clinically evident disease, the most deleterious form of prostate cancer. 
Unfortunately, as it stands today, prostate cancer screening has not been able to 
consistently delineate these tumors from the non-deleterious variety. As a result, a 
multitude of unnecessary, potentially life altering prostate procedures continue to occur.  
A major concern with PC screening is proper classification of disease severity. 
Simply identifying ‘prostate cancer’ is not enough information to determine the 
appropriate course of treatment. A study performed in 1994 provided insight on the 
current ambiguity that surrounds prostate cancer. The study looked at the impact stage A 
PC had on men who elect for radical prostatectomy surgery. Twenty-six percent of the 
157 men who had undergone radical prostatectomy were afflicted with insignificant 
disease.5 In addition, researchers from a 1998 study demonstrated that 84 percent of men 
within their study population would not benefit from radical prostate surgery.22 This data, 
coupled with prior research that demonstrates poor validity and reliability, makes using 
PSA alone a very suspect screening tool for prostate cancer detection.7, 43, 116       
Prostate Cancer Epidemiology 
Prostate cancer is the second leading cause of cancer death in men in the United 
States, accounting for 40,400 cases in 1995, and 8,500 in the United Kingdom.6,10,15 It is 
the most common cancer detected in American men, with more than 230,000 cases 
detected each year.6 It is also the most commonly diagnosed non-skin cancer in most 
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developed countries.10 Over a 10 year period (1985-1995), the reported incidence has 
increased from 85,000 to 244,000.25 The annual incidence of PC does not match the 
prevalence identified on autopsy, where PC is present more than 40 percent of the time in 
men aged 60 years or older.7 It is primarily a disease of elderly men, with PC mortality 
age distribution demonstrating this well. Eight-five percent of men who die from PC are 
above the age of 65.6 Specifically, men aged 75-84 years of age account for the highest 
percent percentage of death (41.7 percent), men 55-64 account for 7.4 percent, 65-74 
(28.4 percent), and 85 or greater (21.4 percent), respectively.7 Younger men (less than 
55) account for only 1.1 percent of the total prostate cancer mortality numbers.18  
Screening Criteria 
 One function of a screening test is to identify the disease of interest in persons 
who are currently asymptomatic and would progress to a clinically evident case if not 
without early identification. For screening to be effective, it must be performed on a 
repetitive basis.19 For screening to be cost-effective, it must be readably available, quick, 
and be of little risk.19 In prostate cancer, if biopsies were performed on all men instead of 
utilizing surrogate markers (i.e. PSA and/or DRE); the assumed result would be better 
reliability and validity. This idea is impractical, given the number of potential problems 
seen with prostate biopsy. Known prostate biopsy morbidities include infection, bleeding, 
incontinence, acute and chronic pain. 
Risk Factors of Prostate Cancer  
The causes of prostate cancer are currently unknown. Known associated risk 
factors for prostate cancer include increasing age, family history, and ethnicity. 
Additional risk factors described with PC include environmental exposures, smoking, 
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dairy products, red meat, animal fat, and biologically plausible fetal exposures (both 
environmental and genetic).10
 Research Question/Study Design 
     The overall goal of this study is to improve the efficiency of PC detection 
through the development of a clinical decision rule that is based on an elevated PSA and 
set of laboratory biomarkers. This measure would be used as a secondary screening test 
(after an initial PSA test) that the patient and clinician can refer to for additional 
predictive information before undergoing a prostate biopsy. This is a cross-sectional 
study, evaluating men from a reference population within the VA healthcare network 
from January 1, 1998 through April 15, 2005. The men are between 40-90 years of age, 
prior military servicemen who utilize the Tampa Veterans Administration medical 
network for their healthcare needs. These men have undergone prostate biopsies as a 
result of an elevated PSA screening test (>4ng/dL) The subjects are classified into one of 
four ‘histology’ groups: biopsy confirmed prostate cancer (PC); biopsy confirmed 
Prostatic Interstitial Neoplasm (PIN); biopsy confirmed Benign Prostatic Hypertrophy 
(BPH); or biopsy confirmed PC negative/BPH negative/PIN negative, to accomplish 
three specific aims.  
Aim 1 – The first aim is to identify biomarkers that are both related to prostate cancer and 
have the capability of improving the efficiency of PC screening. Within the prostate 
biopsied groups of men, evaluation of routinely ordered laboratory biomarkers 
(hematologic, serologic, and urologic) will be performed to assess for significant 
relationships between the biomarkers and histology groups.    
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Hypothesis 1: Among VA patients who have undergone prostate biopsies secondary 
to a PSA value of >4ng/dL, specified lab biomarkers* among cases of prostate 
cancer will differ significantly from those among VA patients without prostate 
cancer.     
Aim 2 - Upon completion of the above aim, statistical models (including biomarkers and 
known PC risk factors) will be developed to determine which can best predict the 
probability of prostate cancer. These potential screening models will be compared to the 
current screening tool (PSA only), to evaluate for improved overall effectiveness in 
prostate cancer detection and reduction in prostate biopsy. The inclusion of additional 
predictors offers potential for decreasing unnecessary prostate biopsies and false positive 
tests; resulting in increased specificity, predictive values, and better overall validity.  
Hypothesis 2: Among VA patients who have undergone prostate biopsies secondary 
to a PSA value of >4ng/dL, the addition of specified lab biomarkers* will improve 
the effectiveness of predicting the presence of prostate cancer when compared to 
PSA alone. 
Aim 3 - The third aim of this study is to assess for a dose-response relationship between 
specified lab biomarkers (surrogates for extra-prostatic disease development) and the 
progression of prostate cancer. If present, this parallel progression would demonstrate a 
gradient between PC and systemic disease. For example, as a patient afflicted with 
prostate cancer progresses through stage A to stage D, development of other systemic 
diseases (i.e. Iron Deficiency Anemia), would follow a similar progression of disease 
severity.  Thus lab values associated with these systemic diseases should move further 
from there “normal” values. If this relationship can be demonstrated, it would be possible 
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to classify PC patients in terms of likely benefit from invasive interventions verses 
employing an expectant observation approach.       
Hypothesis 3:  Among VA cases of histologically confirmed prostate cancer, there 
exists a gradient between specified lab biomarkers* and increasing stage of prostate 
cancer. 
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Chapter II: Literature Review  
The ideal prostate cancer screening tool would be one that identifies men with 
prostate cancer that is not yet clinically evident. The test characteristics would include a 
very high validity (demonstrated thorough high sensitivity and specificity), reliability, 
and predictability. It would be relatively inexpensive (when compared to follow-up 
diagnostic tool), minimally invasive, and readably available. Additionally, upon its 
implementation, mortality and morbidity rates secondary to prostate cancer would 
decrease with time. Unfortunately, we currently do not have such a screening tool. As a 
result, researchers are continuously looking at ways to improve prostate cancer screening.  
Prostate Cancer Screening Tools 
 
PSA   
 Prostate specific antigen is protein generated out of the epithelial tissue of the 
prostate. It is released primarily from the transitional zone of the prostate.41 Multiple 
biological processes can elevate serum PSA. Cancer, BPH, acute bacterial prostatitis, 
chronic bacterial prostatitis, nonbacterial prostatitis, prostate stones, urinary tract 
infections, ejaculation, bicycle riding, and manual manipulation are all examples of 
potential sources of PSA elevation.1  
PSA is a gene product from chromosome 19 and has a molecular weight of 
34,000.43 PSA is typically bound to protease inhibitors upon entry into systemic 
circulation.68 The newly bound, ‘complexed PSA’ (cPSA), most often partners with the 
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a1-antichymotrypsin (ACT).68 Prior research has demonstrated that the ACT form of PSA 
occurs more often in men with prostate cancer.69  
Prostate specific antigen was first identified in 1979, and not long after its 
discovery, researchers began to use it within prostate cancer screening. In 1986, the U.S. 
Food and Drug Administration approved the first commercial immunoassay for use in the 
treatment of prostate cancer patients.7 
The serum levels of PSA correlates with the volume of both benign and cancerous 
cells.  PSA was first used as a screening test for prostate cancer in 1986.7 It was evaluated 
again in epidemiologic research in 1987 and 1988, where it was examined for its 
usefulness in clinic utilization as a predictor for final pathologic stage in patients with 
localized PC, and after radical prostatectomy.7 In both cases, PSA was found to be a 
useful tool in monitoring PC patients for detection of recalcitrant or recurrent prostate 
cancer after radical prostatectomy.   
PSA has been employed mostly as a tool for prostate cancer screening. False-
positive results remain high with total PSA. It is estimated that 1 out of every 5 men who 
have pre-clinical localized prostate cancer have a PSA value of less than 4 ng/mL.72 The 
estimated positive predictive value of PSA (4ng/dL) is 30 percent.71 PSA is also used as a 
tool for staging and for monitoring of cancer reoccurrence post prostatectomy.73 Prior 
studies have demonstrated post radical prostatectomy, elevations of PSA are a reliable 
and valid sign of recurrent cancer.73  
Digital Rectal Exam 
An additional prostate detection tool is the Digital Rectal Exam. Although the 
sensitivity and specificity of digital rectal exam (in prostate cancer detection) is 
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considered poor, its relative convenience, lack of cost, and minimal side effects make 
DRE a frequent tool utilized by practitioners in prostate gland evaluation. The DRE is the 
most frequently performed prostate exam in clinical medicine today. Despite the lack of 
accuracy, it is recommended by the American Cancer Society, American College of 
Radiology, and the American Urological Association that all men above the age of 50 
undergo routine annual DRE.16 Although previous studies on DRE sensitivity and 
specificity vary widely due to the specific population under study, a study performed in 
1988 estimated the sensitivity at .8 percent and specificity at .25 percent, respectively.61 
The positive predictive value is also mottled, with studies demonstrating PPV values 
from 6 to 50 percent.30, 61, 62  
On physical exam, the posterior wall of the prostate gland can be palpated.4 
Prostate cancer arises primarily within the periphery of the gland, thus allowing for 
potential identification of large tumors by DRE. The characteristics of a prostate mass 
have been previously described as indurated, poorly differentiated, and hard.63  
Prior studies have demonstrated many limitations of DRE. These limitations 
include poor identification of small, organ confined tumors, selection biases (on age and 
subjective history), and variability due to the skill level of the practitioner performing the 
exam.63   
PSA Velocity 
  
 Over the last decade, the rate of PSA change has been gaining interest as a 
potential predictor of early prostate cancer. In a 2004 study recently published in JAMA, 
researchers found that the way PSA levels change over time (velocity) may be a more 
important factor than any specific level of PSA.23 This prospective study included 1,095 
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men who had undergone radical prostatectomy. The authors reported that the risk of 
death secondary to metastatic prostate cancer was directly related to the rate of velocity 
change in sequential PSA serum levels, which appeared to be more accurate than 
standard PSA testing alone. Comparing men whose PSA increased 2 ng/dL or greater to 
men without change in their PSA levels, the risk ratio (IDR) was found to be 2.8. This 
implies men with rising PSA values are nearly three times more likely to die within seven 
years of radical prostatectomy (than men without rising PSA values).23   
PSA velocity is defined as the change of PSA value over a defined time period.7 It 
is theorized that the PSA levels which increase more rapidly than expected over a 
specifically defined time period are more likely to be caused by prostate cancer than a 
benign, less aggressive prostate problem. PSA velocity is normally assessed by 
determining the percent change in serum PSA levels over a year basis. The ‘acceptable’ 
rate of change is still open to debate, although a change of greater than or equal to 
.75ng/dL per year is highly suspicious of prostate cancer.26  
Carter et al. were the first to assess the functionality of PSA velocity change as a 
potential tool for prostate cancer detection. This retrospective study looked at 54 serum 
samples taken from men enrolled in the Baltimore Longitudinal Aging Study.  The 
evaluated men were grouped as biopsy confirmed prostate cancer patients, BPH patients, 
or the control group. In men whose PSA levels were below the elevated ‘positive’ marker 
(4ng/dL), it was shown that an increase of .75 ng/dL or greater would identify PC in men 
with a test sensitivity and specificity of 80 percent and 66 percent, respectively.26 PSA 
velocity identified prostate cancer cases from non-cancerous disease with a specificity of 
90 and 100 percent when evaluating accrued PSA levels.26 Their discussion centered on a 
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potential biopsy reduction of upwards of 30 percent among men with a prior negative 
biopsy and persistently elevated PSA levels. Additionally, when compared to the 
standard total PSA serum evaluation, PSA velocity may be a more valid early identifier 
of prostate cancer.     
A considerable drawback to the widespread use of PSA velocity is the intra-
individual variation in men with regards to their PSA values. This variation is irrespective 
to the state of disease within the prostate. A change of .75ng/dL might be predictive of 
prostate cancer, but as described by Carter et al., three consecutive PSA measurements 
are needed over an 18 to 24 months time window to clearly distinguish the prostate 
cancer cases from that of the non-cases.27 Given this key data, it is unlikely that PSA 
velocity (in its current form) will be incorporated in a national prostate cancer screening 
program as a substitute (or adjunctive) tool for total PSA.   
Age specific cut-off points 
  Many researchers and clinicians have advocated the use of age specific 
cut-off ranges as a way to better to screen for prostate cancer.86 Proponents for this 
screening method argue that using a higher cut-off point for older men will not result in 
increased PC morbidity and mortality events. It has been previously established that the 
prostate size increases with age. As the volume of prostate tissue increases with aging, so 
does the potential for elevated PSA values.85 The hypothesized benefit of having a higher 
cut-off value for older men is an overall drop in the number of unnecessary biopsies that 
would occur each year.84 Additionally, using a cut-off value that is under 4 ng/dL for 
younger men would increase the likelihood of detecting asymptomatic tumors. It is a 
given that younger men have a longer life expectancy than older men, and proponents 
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believe it is more important to detect the disease in the young. This increased life 
expectancy places them at increased risk of prostate cancer development, progression, 
metastasis, and death.27  
Over the last 12 years, published studies have produced conflicting data on this 
topic. Initially, it appeared that results from a 1993 study pointed towards potential 
improvement in disease detection with the utilization of age specific cut-off points.27 The 
study by Oesterling et al., focused on developing the specific cut-off point values.  The 
researchers found that by increasing the cut-off points as the age groups increased, the 
number of unnecessary biopsies could be reduced. Moreover, the large percentage of 
missed prostate cancers was classified as ‘not clinically important’. For example, within 
the 60-69 age strata, nearly 20 percent of all biopsies would not have been performed, 
resulting in missing less than 5 percent of the total tumor amount (within the evaluated 
age strata). Additionally, 95 percent of the ‘missed’ cancers were deemed ‘clinically 
irrelevant’.27 In their follow-up study, the following age specific PSA levels were detailed 
and recommended:  
40 to 49 years of age PSA value 2.5ng/dL or greater 
50 to 59 years of age PSA value 3.5ng/dL or greater 
60 to 69 years of age PSA value 4.5ng/dL or greater 
70 to 79 years of age PSA value 6.5ng/dL or greater 
Table 1. Age-Specific Reference Ranges: (Partin and Oesterling et al., 1996). 
The authors stated by initiating the above cut-off values in place of the standard 4ng/mL, 
an additional 74 men (who had values below 4ng/dL) of the nearly 4,600 males sampled 
would have been identified as having prostate cancer.27 Of these 74 men, 14 were 
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identified as having ‘unfavorable pathology’, indicating increased likelihood that their 
tumor would cause significant morbidity or mortality if left untreated. The authors 
concluded that by incorporating the age specific reference ranges in conjunction with 
DRE, younger men at higher risk for prostate cancer development would be identified, 
and elderly men would be less likely to undergo unnecessary biopsies. They additionally 
stated that elderly men were more likely to present with less aggressive cancer when 
compared to their more youthful counterparts, providing more evidence to support 
changing the reference ranges.27  
 However, over the last decade numerous new studies have been published that 
seem to suggest age-specific cut off points are problematic. These studies demonstrate 
that many of the older men in the study in fact had aggressive tumors, often with Gleason 
score 7 or greater in grade type. A 1998 study reported that of the men who would not 
have been biopsied on the age-specific reference range algorithm, 1 out of 5 had 
‘aggressive cancer’.84 Similar findings have been additionally published, demonstrating 
the potential for a total biopsy reduction of 8 to 15 percent, but with 15 to 30 percent of 
clinically important cancers being overlooked.85, 86 As a result of the inconsistent findings 
between published research, incorporation of age-specific cut-off values has been met 
with skepticism and has not occurred on a national level. 
PSA Density 
  
 PSA density is determined by dividing the total PSA by the prostate volume.42 It 
has been suggested that the PSA density could control for total PSA increase related to 
the natural prostate enlargement correlated to age. PSA density was first reported to 
delineate between elevations related to prostate cancer and BPH in 1987.39 The 
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researchers concluded that after controlling for confounding factors, PC is ten times more 
likely to be the underlying etiology of total PSA elevations when compared to BPH. To 
further strengthen the PSA density role in delineating PC from BPH, researchers in a 
1992 study of men referred to Urologic specialty center found that PSA density could 
better differentiate PC cancer patients from BPH patients.40 The study looked at 595 
patients who had an initial total PSA value of between 4-10 ng/dL. Evaluating men who 
had either prostate cancer or BPH, there was a statistically significant difference in the 
PSA density between the two groups (p<0.001), while the difference of the total PSA 
between the two groups was not.40 Furthermore, additional studies found significant 
differences exist in the PSA density of men with PC compared to non-cancerous prostate 
conditions, although statistical significance could only be found in the 4 ng/dL groups.41       
 Recent PSA density research has looked more closely at the transitional zone 
volume as opposed to the volume of the entire prostate. The transitional zone is one of 
three distinctive histologic regions within the prostate.41 The two additional regions 
include the peripheral and central zones. It is believed the transitional zone constitutes 
less than 5 percent of the total volume of the prostate.41 Given that the majority of 
prostate tissue growth and PSA outflow occurs in the transitional zone, it has been 
hypothesized that focusing on this particular region as opposed to the entire gland might 
result in better prostate cancer prediction.  A 1998 study looking at transitional zone PSA 
density and percent free PSA with and without total PSA demonstrated that at 0.22 ng/dL 
or above, transitional zone PSA density would have prevented almost 25 percent of all 
evaluated negative prostate biopsies would have been avoided.42 
 The limiting issue surrounding the widespread use of total prostate PSA density 
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and transitional zone PSA density is that they both require ultrasound imaging of the 
prostate for the accurate determination of prostate volume. The most common ultrasound 
imagining available is the Transrectal ultrasound (TRUS), and it has previously reported 
that the volume calculations obtained from the TRUS are not always exact, further 
limiting its implementation. At this time the recommended usage of PSA density is for 
the recalcitrant PSA elevations with a previous negative biopsy for prostate cancer.16
Gleason Score 
 An important predictive characteristic of prostate cancer is the appearance of the 
glandular tumor cells (which assists in defining the aggressiveness of the cancer). The 
Gleason score was derived to describe the microscopic appearance of the glands that 
form prostatic cancer.106 Prostate cancer of a low-grade is less likely to spread, while 
increasing grades are at higher risk of metastasis.16 The Gleason score is based on the two 
most prominent areas of PC activity as identified by a pathologist on histologic 
examination.4 Each prominent area is given a score of 1-5, with 1 being well 
differentiated, and 5 being poorly differentiated (implying a more aggressive 
appearance).4 The two scores are added together, and this number is called the “Gleason 
score”.106
A Gleason score of 2-4 is considered low grade (less aggressive); 5-7 is 
considered moderate grade (average aggression); and a Gleason score of 8-10 is 
considered high grade (most aggressive).16 A man with a Gleason score above 7 is at 
increased risk of dying from PC than a man with a Gleason score of 7 or below.106    
Transrectal Biopsy 
 In an attempt to heighten the understanding of prostate tumor location, 
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aggressiveness, and increase accuracy in determining PC presence, ultrasound guided 
transrectal prostate biopsy has been incorporated into the standard of care for many PC 
patients. Originally, prostate biopsies were performed through a transperineal approach.63 
This technique was replaced due to the limited visibility it offered in terms of biopsy 
needle placement. The transrectal biopsy has been demonstrated to be a superior tool in 
providing information on appropriate needle placement in cases where prostate cancer is 
suspected.62  
 The biopsy is performed with an 18 gauge, spring loaded needle. The biopsies are 
performed in a systematic fashion, with an average of 6-10 sextant biopsies performed 
per biopsy procedure.65 Controversy has increased recently over the amount and location 
of the TRUS biopsies. Many PC experts recommend increasing the number of biopsies 
performed per session, and increasing the area under evaluation. Typically the biopsies 
are performed within the periphery of the gland, given that the majority of PC arises 
within this prostate zone. However, many investigators have demonstrated that the rate of 
prostate detection from biopsies is inversely proportional to the size of the prostate.63    
 PSA Elevators 
Prostate Cancer  
 Prostate cancer is comprised of an assorted set of tumor subtypes. Although the 
heterogeneity of prostate cancer is well documented, the natural history of the disease is 
poorly understood. All types of prostate cancer are androgen dependent. The androgen 
receptor is the prime regulator of both benign and cancerous prostate epithelial cell 
growth.36 Upwards of 95 percent of all PC tumors are adenocarcinomas located along the 
edge of the prostate.64 Greater than three quarters of prostate adenocarcinomas are 
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multifocal in origin.45 Transitional cell tumors account for 4 percent of all PC, and 
squamous cell tumors are very rare, making up the final 1 percent of the prostate cancer 
total.  
Extraprostatic extension of prostate tumors typically occur posteriorly and 
posteriolaterally along a plane of least resistance into the perinueral space.65 Local 
extraprostatic invasion commonly occurs in the seminal vesicle, urethra, bladder, and 
often continue to the local lymphatic chains.  
The skeleton is the most frequent system of distant PC metastasis. It has been 
previously reported that upwards of 85 percent of patients dying of this cancer have bony 
metastasis present. Additional systems associated with distant PC metastasis include the 
lungs, brain, lymph nodes, and viscera.67   
The tumor volume has been shown to correlate with its aggressiveness. Small 
tumors are unlikely to spread outside of the prostate. Conversely, tumors that achieve 
extraprostatic status and are greater than 4cc in volume are at increased risk for both 
seminal vesicle and lymphatic invasion.66     
Staging and grade of prostate cancer is summarized below: 
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Stage A Non-palpable 
confined to 
prostate 
Gleason 
score 2-4 
Well 
differentiated 
cells 
Best prognosis 
Stage B Palpable confined 
to prostate 
Gleason 
score 5-6 
Moderately 
differentiated 
cells 
Better 
prognosis 
Stage C Locally spread 
outside of prostate
Gleason 
score 7 
Moderately 
poorly 
differentiated 
cells 
Guarded 
prognosis 
Stage D Distant metastasis Gleason 
score 8-10 
Poorly 
differentiated 
cells 
Poor prognosis 
Table 2. Prostate Cancer Stage and Grade 
Prostatic Interstitial Neoplasm (PIN) 
 Prostatic Interstitial Neoplasm is thought to be a precursor for prostate cancer.58 It 
has been previously described as a proliferative mass made up of prostatic acini epithelial 
cells that are dividing and multiplying at increased rates.57 The cells are not cancerous in 
their morphology, although their presence on prostate biopsy suggests increased 
probability that prostate cancer development will occur in the patient under evaluation.58
 Prostatic Interstitial Neoplasm is a dysplastic lesion; classified as low (grade I), 
medium (grade II), and high (grade III).57 Low grade PIN does not have the same 
likelihood of progression to prostate cancer as medium and high grades.59 The reported 
prevalence of medium grade PIN identified in benign prostates has been reported at 10-
70 percent, respectively.57 The prevalence of high grade PIN in cancer free prostates is 
estimated to be between 15-20 percent.57 In specimens positive for prostate cancer, high 
grade PIN it is identified in approximately 33 percent of autopsied samples, and 70-100 
percent in surgical samples status post radical prostatectomy.59    
 Currently, prostate cancer clinicians and researchers do not have a universally 
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recommend treatment regimen for Prostatic Interstitial Neoplasm.60 Chemoprevention, in 
which androgen deprivation techniques are employed to decrease the progression of PIN 
and possibly delay or arrest PC development, are currently under evaluation in clinical 
trials. Radiation therapy has been reported to decrease PIN.60 Lycopene, soy, and certain 
vitamins (D, E) have been previously identified as potentially protective in prostate 
cancer development and therefore have been described as ‘potentially helpful’ in 
preventing PIN development.56  
 Prostatic Interstitial Neoplasm follow-up is not clearly defined. In general, it is 
recommended to have an additional trans-rectal biopsy within six months, and again 
possibly every 1-2 years thereafter. Routine PSA draws are additionally recommended.60
 The correlation between PIN and PSA elevations and the effect PIN has on 
screening is poorly understood. In general, it is thought that prostatic interstitial neoplasm 
does not elevate PSA levels.59 The screening for PIN is not recommended.58 Numerous 
prospective studies on PIN are currently ongoing, but as of now the impact of PIN on 
prostate cancer screening is unknown. 
Benign Prostatic Hypertrophy 
 Benign Prostatic Hypertrophy (BPH) is a frequent elevator of serum total PSA.87 
The underlying etiology of BPH is poorly understood. Hypothesized etiologies include 
endocrine activity, diet, activity, and familial genetic factors.88 The incidence of BPH is 
related to increasing age.4 The prevalence of BPH follows a linear trajectory with age, as 
BPH has been identified on autopsy in 22 percent of men aged 41-50 years old, with 
linear increasement to over 75 percent in men older than 80 years.87 The genesis of 
Benign Prostatic Hypertrophy is typically in the periuretheral and transitional zones of 
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the prostate.89 Conversely, prostate cancer originates in the prostate’s peripheral zone.18  
 Subjective symptoms of benign prostatic hypertrophy are comprised of both 
irritative and obstructive voiding complaints.88 Irritative symptoms include urinary 
urgency, frequency, painful urination (dysuria), and increased urination at night 
(nocturia).88 Obstructive symptoms include urinary hesitancy, weak urine stream, 
intermittent voiding, and weakened voiding force.88    
 Clinical objective evidence of benign prostatic hypertrophy includes localized or 
global enlargement of the prostate, as identified on digital rectal examination.88 
Additionally, supra-pubic abdomen distention may be palpable, indicating urinary 
retention secondary to the prostatic hypertrophy.90  
 Laboratory finding seen in conjunction with BPH include elevated PSA, blood 
urea nitrogen (BUN), creatinine, and less commonly hematuria, positive nitrates, and 
leukocytosis (if a urinary tract infection is concomitantly present).88  
Imagining studies are frequently performed with benign prostatic hypertrophy. They 
include Intravenous Urography, Uroflometry, and Cystourethroscopy.88 Uroflometry is 
considered the most useful urodynamic tool in assessing the degree of BPH, with a urine 
flow of less than 10mL per second indicating advanced obstruction secondary to the 
prostatic hyperplasia.87   
 Treatments for benign prostatic hypertrophy fall into one of three broad 
categories: medication, surgical, and minimally invasive treatments.87Medication 
treatments include a multitude of androgen deprivation medications, although these 
medications often result in decreased libido and sexual function.90 The prostate contains 
a1adrenoceptors, that if blocked have been shown to result in contraction of prostate 
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tissue.89  Therefore alpha1blockade medication has been shown to improve the irritative 
and obstructive symptoms of BPH.89 Surgical treatments involves removal of the 
enlarged prostatic tissue and can be performed through either the urethra or a traditional 
incision.87 Transurethral resection of the prostate (TURP) has been identified as an 
effective treatment of decreasing the symptoms of BPH with relatively low morbidity and 
mortality statistics.87 The reported mortality rate is estimated 0.1 percent, with a 
morbidity rate of less than 20 percent.89 The most common side effect of TURP is 
retrograde ejaculation and bladder neck contracture.88   
Additional minimally invasive techniques are currently under development and 
offer the potential for decreased morbidity and quicker post-operative recovery. Balloon 
dilation, ultrasound laser guided energy, and transrectal microwave hyperthermia are 
some of the techniques currently under study.79 The use of these techniques is in the 
investigational stage, with ongoing clinical trials results pending.79  
Prostatitis is an inflammatory process of the prostate.80 It has been described 
previously as one of three conditions: acute bacterial, chronic bacterial, and nonbacterial 
prostatitis.80  
Acute bacterial prostatitis  
 Acute bacterial prostatitis is characterized by complaints of fever; irritative 
voiding symptoms, perineal pain, and exquisite tenderness on DRE.80 Urinalysis 
frequently demonstrate pyuria, bacteriuria, and hematuria.79  Laboratory findings include 
an elevated leukocytosis and left shift.79 Positive urine cultures are present, with the vast 
majority of cases caused by gram-negative rod organisms.79 Specifically, Escheria coli, 
Pseuedomonas, and (less commonly) Enterococcus are the most frequent causal 
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organisms identified.78
 The hypothesized routes of infection include refluxed infected urine into the 
prostatic duct and an external infectious agent that ascents up the urethra.80 Differential 
diagnosis for acute bacterial prostatitis include acute pylonephritis and acute 
epididymitis.79 Treatments initially includes intravenous antibiotics and hospitalization. 
Upon reaching afebrile status for 48 hours, oral antibiotics can then be initiated. Oral 
antibiotics are commonly utilized for 4-6 weeks to ensure complete eradication of the 
offending organism is achieved.80  
 Complications of acute bacterial prostatitis include urinary retention, 
epididymitis, pylonephritis, and chronic prostatitis.80 With aggressive effective treatment, 
complications are considered rare.79   
Chronic bacterial prostatitis 
 Chronic bacterial prostatitis can arise secondary to an acute prostate infection, but 
often times afflicted men have no history of such an event.80 Patients can be 
asymptomatic, but they often complain of mild irritative voiding with dull suprapubic and 
perineal pain.79 Urinalysis are often normal, but expressed prostatic secretions display 
increased lipid-laden macrophage leukocytes (>10 per high powered field).79  
 The primary difference between acute and chronic prostatitis revolves around 
treatment. Antibiotics have difficulty reaching therapeutic intraprostatic levels without 
the acute inflammation seen with acute bacterial prostatitis.78 Therefore, treatment for 
chronic bacterial prostatitis revolves around nonsteroidal anti-inflammatory 
medications.78  Trimethoprim does penetrate the prostate, therefore it is often given for 3-
4 months to complete the treatment regimen.80
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Nonbacterial Prostatitis 
 Nonbacterial prostatitis is the most common of prostatitis syndromes, and its 
etiology is unknown.78 It is considered a diagnosis of exclusion, with some of the 
hypothesized causes including viruses, sexual transmitted diseases, and autoimmune 
disorders.78 Physical exam with nonbacterial prostatitis is similar to the chronic bacterial 
condition, although prostatic secretion cultures are negative for organisms.78  
 Treatment for nonbacterial prostatitis include nonsteroidal anti-inflammatory 
medications, sitz baths, and possibly dietary modifications if the symptoms seem to 
correlated with food.80 Trials of antibiotics are encouraged if the condition is believed to 
be secondary to a sexually transmitted disease.80 Unfortunately for many patients, this 
condition is often recalcitrant to treatment and patients often experience recurrent bouts 
of pain. Although annoying, serious morbidity secondary to nonbacterial prostatitis has 
not been identified.80   
 In addition to the above known PSA elevators, it is believed that a recent digital 
rectal exam, urinary tract infection, sexually transmitted disease, ejaculation, or extended 
bicycle riding episode can all temporarily elevate PSA values as well.  
  Treatments for PC – confined to the prostate  
 Prostate cancer that is identified while confined to the borders of the prostate offer 
more treatment options than a tumor that has spread locally or systemically. Younger 
patients or patients with aggressive disease have many different options for their care, 
and because there is not one overt superior treatment, the specific treatment course is 
often determined by a patient’s decision. The treatment options for confined prostate 
cancer can be grouped within two categories: radiation and surgery.  
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Radiation treatments have two basic subcategories: internal and external radiation. 
Internal radiation (Brachytherapy) is usually provided through radioisotopes needle 
implants.43 Brachytherapy utilizes radioactive ‘seeds’, that are usually smaller than 2 
millimeters in size, 75 to 100 of which can be typically implanted into the prostate during 
the procedure.44 One significant advantage of internal radiation is that it is a one time 
procedure, external radiation requires multiple treatments.10 External radiation relies on 
imaging tools such as ultrasound, computed tomography (CT) scans, and pulse intensity 
beams to assist in delivering high-dose beams of radiation to the prostate while protecting 
the surrounding Genitourinary organs.44 This type of radiation treatments lasts 
approximately two months, and usually includes over 40 treatment encounters.46 
Radical Prostatectomy is the most common surgical approach in removing 
prostate cancer from a patient.45 There are a multitude of surgical approaches with this 
surgery, but the two most common approaches are the retropubic approach and the 
perineal approach.81 The former is used when there is a need for lymph node biopsy, 
while the latter is an acceptable approach for organ confined; low-risk disease is 
present.81     
 Over the last decade laparoscopic surgery has been used more frequently for 
radical prostatectomy surgery.45 This type of procedure is gaining in acceptance because 
there is reportedly less blood loss during surgery, and less post-operative complications.45 
Access to the lymph nodes for sentinel and multiple node biopsy is maintained, and 
patients return to activities of daily living on average two weeks faster than the traditional 
surgery. The primary drawback to this technique is the highly technical nature of the 
procedure, which limits the number of surgeons qualified to perform the surgery.     
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 Cryosurgery is a technique in which the prostate is frozen by liquid nitrogen (or 
argon gas); killing the cancerous tumors while limiting the destruction of healthy tissues 
to a minimum.45 This technique uses ultrasound and MRI to guide the cryoprobe as it 
distributes the liquid nitrogen. This surgery is a safe alternative for patients who are not 
candidates for traditional surgery or radiation, and the procedure can be repeated if 
deemed necessary. Disadvantages of cryotherapy include potential for incontinence, 
impotence, and urinary obstruction. Due to its relative newness, the long term outcomes 
of cryosurgery is unknown.46  
 For men afflicted with prostate cancer which is small, organ confined, and 
asymptomatic, expectant observation is often employed.81 Additionally, men with a life 
expectancy of ten years or less, or patients with comorbidities that suggest they are likely 
to die from something other than their prostate cancer, often employ this strategy as 
opposed to more aggressive treatment options.81 The focus for these patients usually 
centers around quality of life, healthy lifestyles, with bi-annual PSA evaluations to 
monitor their disease status. Benefits of watchful waiting include the avoidance of 
surgical and radiation side-effects, avoidance of prolonged recovery period, and the 
potential to maximize their quality of life. Disadvantages of expectant observation 
include the lost benefit from early treatment, metastatic spread of the tumor, and early 
than expected death.81  
Local Spread treatments 
 Prostate cancer that has penetrated the external capsule of the prostate is treated 
differently than organ confined disease. Commonly, locally spread PC is described as 
having either ‘minimal capsular penetration’ (MCP), or ‘extensive capsular penetration’ 
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(ECP). The ECP subset includes PC that has invaded the seminal vesicle, bladder neck, 
or both.77  
The treatment options for patients of both categories are quite extensive. Radical 
prostatectomy with inclusion of surrounding structures is the typical surgical treatment 
for the MCP subset. For men with ECP, the benefit of radical prostatectomy surgery is 
questionable. Prior research has demonstrated an increased risk of PC relapse for men in 
this subset.82 In a retrospective study looking at ten year follow-up data, researchers 
found that 46 percent of post-radical prostatectomy patients with low grade, locally 
spread disease, had PC relapse within ten years. In addition, the same study determined 
that 58 percent of post-radical prostatectomy patients with high grade disease 
demonstrated clinical evidence of PC within the ten year time period.95    
Many additional nonsurgical treatments are routinely employed for locally spread 
PC. These treatment options include irradiation, hormone therapy, cryosurgery, and 
combination therapies (androgen deprivation combined with medication, surgery or 
irradiation). 
 The application of nonsurgical treatment modalities for locally spread PC has 
increased significantly over the last ten years. Prior studies have shown survival rates of 
nonsurgical treatments to be similar with that of radical prostatectomies, without the 
associated morbidities that are often seen with major surgery.77 The use of nonsurgical 
monotherapies is controversial in that relapse disease has been reported to be high 
(relative to combination therapy). Relapse of PC within ten years is estimated at 55-65 
percent for patients receiving radiotherapy as a single treatment agent.93      
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Distant Spread  
 Metastatic PC treatments focus on palliative and combination therapies. The 
typical first line treatments center on decreasing circulating androgen levels.92 PC is 
hormone dependent, and the decrease of androgens will slow its spread. A primary 
therapy of metastatic PC is the gonadotrophin releasing hormone (GnRH) analogous. In 
survival analysis studies evaluating patients with metastatic prostate cancer treated with 
GnRH, estrogen, or orchiectomy, significant differences in survival time were not 
observed.94 This data, coupled with the known cardiovascular risks of estrogen, and the 
general patient disdain for orchiectomy, has made GnRH compounds well liked by both 
PC clinicians and patients.  
 Anti-androgens are commonly used as a part of a combination treatment regimen 
for advanced PC. Prior clinical trials have shown Flutamide and Cyproterone (commonly 
used anti-androgens) to be correspondent to estrogen in their anti-androgen actions with 
decreased cardiovascular risk profiles.93 They are not without side effects, however, as all 
medications within this class demonstrate varying degrees of gynocaemastia, gastro-
intestinal derangement, and erectile dysfunction.93   
    Hormone therapy has been associated with improved PC survival time if used in 
combination with other treatment modalities.93 Finesteride is a 5-alpha reductase inhibitor 
that acts by blocking the conversion of testosterone to dihydrotestosterone.94 Clinical 
trials looking at Finesteride are currently underway, with early results demonstrating 
evidence of a synergistic interaction between it and traditional anti-androgen 
medications.  
 Chemotherapy is utilized as both a combination therapy option and as a single 
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agent medication. Although palliative benefits have been realized (when used in 
combination with steroids), increased survival has not been demonstrated.92
Prostate Cancer Relapse 
Relapse of PC (post primary treatment) does occur, with prevalence rates 
estimated at 11 percent for patients with a pre-operative PSA velocity of 2ng/dl/year or 
less.11 When relapse occurs, the median time until early biochemical activity is 2 years; 
with the median time until clinical evidence at approximately 3 years.93 Upon detection 
of relapse (increasing PSA values on three consecutive tests), a multitude of different 
treatments can be initiated. Castration, in combination with androgen blockers, 
corticosteroids, and radiotherapy, is often employed. Radiotherapy in particular is 
beneficial in patients with skeletal metastasis. Many advanced therapies for both 
metastatic and relapsed PC are limited secondary to high cost and geographical 
availability.  
Hematologic Complications of Prostate Cancer 
 It is known that patients with prostate cancer routinely present with complications 
outside of the prostate. Patients with advanced prostate cancer often present with 
objective hematologic findings that are secondary to either the side effects of PC 
treatment, unrelated causes, or the cancer itself.29 Despite this commonly known fact, 
(and fruitful advances in other areas of prostate cancer research), the relationship between 
serologic and urinary disorders and prostate cancer has been largely ignored.  
It is also known that PSA values can be elevated due to a many prostate 
conditions, but it is unlikely that PSA elevations secondary to non-cancerous etiologies 
will cause changes to other body systems (represented by the lab biomarkers). In prior 
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published research, advanced prostate cancer has been indisputably identified as a cause 
for such laboratory changes. In a study performed by Strum SB, et al, anemia in varying 
severity was found as a frequent complication of advanced prostate cancer. The two 
primary types of anemias found with prostate cancer are Iron Deficiency Anemia (a 
subset of microcytic anemia), and anemia of chronic disease (either 
normocytic/microcytic anemia).  
The following is a description of hematologic conditions and laboratory 
biomarkers that have been associated (directly or indirectly) with prostate cancer.    
Anemia 
 Anemia is a known frequent complication of prostate cancer.32 Upon 
identification of anemia in a prostate cancer patient, it is important to correctly diagnosis 
the sub-category present, as the underlying etiology is then more easily identifiable. In 
the presence of prostate cancer, anemia is likely a result of the prostate tumor itself, the 
provided treatment, or secondary to an unrelated biological process.29 Iron deficiency 
anemia (IDA) is the most common type of anemia found in medicine, and in prostate 
cancer as well. Iron deficiency anemia is a sub-type of the Microcytic anemia group.30 
Microcytic anemia is defined as an anemia with a mean corpuscular volume of under 
80fL.33 Thalassemia is another commonly found type of Microcytic anemia, although it 
correlation with prostate cancer is rare.33 IDA in any type of cancer patient is frequently 
associated with chronic covert blood loss from either the genitourinary or gastrointestinal 
tract.29 Anemia secondary to a local prostate tumor extension into the rectum and/or 
colon resulting in bright red rectal bleeding has been reported.92    
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Hemoglobin 
 Hemoglobin is a protein that carries oxygen from the lungs to the tissues and 
organs of the body, and it also transports carbon dioxide to the lungs for exhalation. A 
hemoglobin test value measures the amount of hemoglobin in the blood sample. A value 
less than 13.8 gm/dL indicates a value out of the normal reference range and is an 
indicator of potential hematologic problems.  
 Hemoglobin has been studied as a predictive factor in recalcitrant prostate 
cancer.34 Multiple published studies have reported that a low hemoglobin value is an 
independent risk factor for deleterious survival outcomes in patients with hormone 
refractory prostate cancer.91 It has been hypothesized that prostate cancer cells can exert 
an effect on bone marrow that depresses normal erythropoieses synthesis, resulting in the 
decreased hemoglobin values. The effect of prostate cancer on hemoglobin as it relates to 
prostate cancer screening and disease aggression has not been thoroughly evaluated.    
Hematuria  
 Blood may appear in the urine as a result of numerous medical conditions, 
including cancer of the prostate.33 Additional known common risk factors for hematuria 
in men include: internal trauma, kidney stones, vigorous exercise, urinary tract infections, 
prostatitis, glomerulonephritis, and cancers of the bladder, ureters, or kidneys.33  
 Hematuria is a rare initial clinical presenting complaint with prostate cancer, but 
is a common finding in patients with prostate tumors that have spread outside of the 
prostate capsule, but has not yet spread to distant body regions.33 Gross hematuria in an 
adult male should be considered secondary to malignancy until proven otherwise.47 
Terminal hematuria has been correlated in prior research as more likely related to bladder 
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neck or a prostatic source then initial void hematuria. Terminal hematuria is defined as 
the presence of blood at the end of the urinary stream.51  
Urea Nitrogen (BUN) 
 Amino acids from endogenous sources and exogenous proteins generate NH3, 
which is then converted to urea by the hepatic cells. Patients with minimal varying 
degrees of urinary retention or with concealed ureteral obstruction secondary to prostate 
cancer may present with elevations in serum urea nitrogen.17 Urea nitrogen may 
additionally be elevated due to many other factors, including renal failure, drug-induced 
renal failure (i.e. Nonsteroidal anti-inflammatory, Tetracycline drugs, Corticosteroids), 
stress, gastrointestinal bleeding, shock, and volume depletion.21 Other known etiologies 
of elevated BUN include catabolic states and high-protein diets.    
Serum Creatinine  
 Creatinine is produced by the breakdown of muscle creatinine. It is thought that 
creatinine clearance declines by 1mL/minute per year as a person ages. In an adult male, 
serum creatinine that is greater than 1.2 mL/dL is considered above the standard normal 
level.21 Increasing serum creatinine has been correlated in previous studies with 
advancing renal failure due to obstruction and use of certain types of medications 
(Nonsteroidal anti-inflammatory, Aminoglycosides). Decreased serum creatinine has 
been linked to decreased muscle mass and severe liver disease (seen in patients with 
advancing prostate cancer).35      
Proteinuria  
 Elevated levels of protein in the urine of a male patient should warrant a complete 
genitourinary workup. The condition has 12 known potential etiologies in the differential 
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diagnosis, of which malignancy of the lower urinary tract (to include prostate cancer) is 
among them.21 Elevated urine protein is most commonly seen in prostate cancer patients 
with systemic disease spread and has not been evaluated as it relates to preclinical, early 
prostate cancer.      
Prothrombin (PT)/Partial thrombin time (aPTT)  
 Disseminated intravascular coagulation (DIC) disorder has been reported as a 
complication of prostate cancer for many decades.74 Disseminated intravascular 
coagulation disorder is an activation of the coagulation cascade, which if untreated can 
lead to multiple blood clots in the bodies blood vessels, as well as severe bleeding and 
organ failure.75 Originally, a succession of case series reported patients with advanced 
prostate cancer demonstrated lower levels of serum fibrinogen (when compared to 
patients without prostate cancer).76 It was hypothesized that the prostate tumor expressed 
a fibrinlytic tissue factor that was the underlying etiology of the DIC disorder.75 
However, later epidemiologic studies pointed to systemic coagulation irregularities as the 
primary culprit.76 The exact incidence of DIC in PC patients has been estimated at 10 to 
15 percent, with more studies reporting rates closer to 5 percent .75 Most published 
studies surrounding DIC and prostate cancer have evaluated DIC incidence in patients 
with localized disease, or in patients post transrectal prostate biopsy. The incidence and 
prevalence of DIC with advancing stage and grade has not been thoroughly evaluated. In 
addition, there is a lack of published research on changes (if any) of Prothrombin Time 
(PT) and Partial Thromboplastin Time (aPTT) values in the presence of prostate cancer. 
Both PT and aPTT are used to evaluate the coagulation system, with increasing levels of 
PTT an independent predictor of DIC.75  
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 Disseminated intravascular coagulation is a systemic disorder that is seen as a 
complication of prostate cancer. The exact rate of occurrence in PC is unknown, and the 
changes seen in hematologic tests as a result of DIC have not been evaluated as a 
predictive tool for advancing stage and grade of prostate cancer. 
Epidemiologic Risk Factors for Prostate Cancer  
Ethnicity 
Prostate cancer incidence and mortality rates are disproportionately higher in 
African-American males than white males in the United States.44 African-American men 
have incidence rates that are two times higher than white males, and their mortality rates 
are 120 percent higher.44 African-American men have a risk rate 1.12 times higher than 
white men for developing prostate cancer in their lifetime.49 Many reasons have been 
hypothesized as to why this is so, with a preponderance of prior research pointing 
towards delay in diagnosis as a primary factor. Diagnoses of prostate cancer is made at 
later stages in African-American men than white men.45 Data on prostate cancer 
incidence stratified on ethnicity from the National Cancer Institutes’ SEER program 
(Surveillance, Epidemiology, and end results) demonstrates the disparities between 
ethnicities well. African-American men have the highest rates of prostate cancer 
incidence, mortality, and aggressive spread of all ethnic groups in the United States.48 
Age adjusted incidence rates for African–American men have risen faster than other 
ethnic groups. For example, from 1973 to 1993 African–American rates have risen from 
62.8 per 100,000 to 270 per 100,000.48 Conversely, white male incidence rates have 
increased from 62.5 per 100,000 to 164 per 100,000 in 1993.48 The increased incidence of 
prostate cancer overall has been attributed to better screening techniques, as well as 
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increased clinician and public awareness.47 However, the improved screening techniques 
and increased awareness does not account for the difference between ethnic prostate 
cancer rates. African-American men have shown a significance difference in prostate 
cancer mortality rates as well. From 1973-1993, the SEER data demonstrates an increase 
in death secondary to PC for African-American men from 39.5 per 100,000 to 56 per 
100,000.48 In comparison, white males had an increase of 20.3 to 24.3 in the same time 
period.48   
 The underlying etiology of these differences has proven difficult to discern. It is 
believed that African-American in general have delayed medical care when compared to 
whites, but it is believed that this care deferment difference does not completely account 
for the ethnic differences that exist in prostate cancer incidence and mortality.17
 No clear genetic link has been demonstrated to account for the differences in 
prostate cancer rates between white and African-American men. A study looking at 
changes of different chromosomal regions in prostatectomy samples noted changes in the 
8p chromosome were seen more frequently in the samples from African-American 
patients than samples obtained from white patients.52 The samples were matched on stage 
and grade and follow-up studies are currently ongoing.    
 Prostate cancer has been shown in previous studies to be a hormonally dependent 
condition.4, 108, 110, 113, 115 Decreasing circulating testosterone in men with prostate cancer 
(orchiectomy vs. medication) has been shown to be an effective PC treatment. 
Researchers have hypothesized that there could be a link between increased levels of 
hormones and subsequent prostate cancer development. Various epidemiological studies 
have failed to demonstrate an association between androgen levels and PC.56, 115 
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Furthermore, African American adult men have not shown any difference in their 
hormone levels when compared to other ethnicities. Studies looking at levels of 
circulating hormones in utero and adolescence have not been thoroughly evaluated, 
although one published study did demonstrate increased levels in utero for African-
American men.56 The relationship between increased hormones in utero and the latter 
development of PC has not been fully evaluated.   
Foods and other environmental factors have been hypothesized as possible 
exposures than could explain the difference in prostate cancer rates between ethnicities. It 
has been previously demonstrated that consumption of dairy products, saturated fats, 
proteins, soy, and lycopene affects (both increasing or decreasing) the probability of 
developing cancer of many different systems, including the gastro-intestinal, urinary, and 
genital tract.99 Although complex, diets high in animal saturated fat have been linked to 
increasing risks of prostate cancer.53 In a study that evaluated diet, exercise, and body 
size with the development of prostate cancer demonstrated for all ethnicities (including 
Asian), the risk of PC increased as animal fat intake also increased.54 In addition, prior 
studies on food consumption tendencies among different ethnicities points towards 
increased fat consumption among African Americans when compared to whites.55 
However, a clear causal pathway between increased animal fat consumption in African 
American men and increased rates of PC has not been demonstrated, and with the 
possibility of significant confounding and misclassification, the likelihood of uncovering 
such an association in the future is unlikely. 
Age  
       The incidence and prevalence of prostate cancer increases as men become older.10 
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The median age at diagnosis for PC is 71 years old.105 The mortality rates associated with 
PC are not as high as incidence and prevalence rates because of the many competing 
causes of death seen with the elderly. The leading cause of death in men aged 55 years or 
higher is heart disease.2 Prostate cancer is the fifth leading cause of death in men.10 In 
2001, 31 percent of male cancer deaths are secondary to lung cancer with only 11 percent 
due to prostate cancer.105 Approximately 35 percent of men aged 60-69 years old have 
PC, compared to an autopsy prevalence of 70 percent in men aged 80-89 years old.9 In 
developed countries, over 80 percent of PC cases occur in men 65 years old or older.105 
The lifetime risk of developing PC is over 3 times greater for a men living in developed 
countries compared to third-world countries. This discrepancy is attributed to greater life 
expectancy and diagnosis at earlier disease states.102, 115  
Family History  
 A positive family history of prostate cancer is a strong risk factor for future 
prostate cancer development.10 Over the last decade; genetic researchers have been 
working towards identifying the specific genes associated with hereditary PC. The goal is 
to create tests that can be used to identify men at high risk for future PC development. 
The exact gene that is responsible for hereditary PC has not been identified, but a positive 
family history does increase risk. This risk depends on certain factors, including the 
number of first degree relatives afflicted with PC and the age at diagnosis. 10, 106, 115  
 In a 1999 prospective study at the John Hopkins Hospital, (which evaluated the 
value of screening individuals at known increased risk for prostate cancer development), 
the researchers evaluated over 10,000 participants and found that men in families with 
two or more cases of PC had 11 times the risk of developing prostate cancer at 60 years 
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of age and 5 times the risk at 70 years of age when compared to a man without a family 
history.106 In addition, this study used Cox regression techniques to control for other risk 
factors and found that men with brothers who had had PC increased their risk greater than 
that of having a father or uncle with the disease.106
Many studies have been performed to evaluate whether PC in a patient with a 
positive family history is different than PC in a patient without a family history of the 
condition. Factors including clinical stage at presentation, preoperative PSA level, 
prostate size, prostate weight, and number of cancer foci present were all evaluated. 
There were no significant differences between the two PC groups in any of the above 
factors.107, 108, 109  
Geographic Location and Diet  
 
Exogenous factors are believed to influence PC incidence. For example, prostate 
cancer rates differ based on geographic location. The United States and Western Europe 
have historically had the highest rates of PC incidence, prevalence, and mortality in the 
world. Conversely, the Asian continent has had the lowest known risk of prostate 
cancer.97 In an ecologic study looking at cancer incidence rates between continents, the 
age standardized annual cumulative incidence rates (CIR) for Asian men were reported at 
1 per 100,000. In comparison, U.S. African American men PC CIR were at 82 per 
100,000, with Caucasian males at 62 per 100,000, respectively.97  
 Additionally evidence that supports exogenous factors influencing PC 
development is seen through migratory studies that have looked at PC trends in Asian 
men living in Asia, the United States, and Europe. The incidence of PC is higher in men 
who migrate from countries of low risk for PC development to countries of higher 
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risk.100, 101 Asian men living in the U.S. or Europe had higher rates of PC incidence than 
their ancestors still residing in Asia.100, 101 When the study controlled for differences in 
the detection time between the different regions, statistically significant differences in PC 
incidence remained.101  
Correlational data also suggests alteration of PC risk can be realized by 
modification of dietary practices. Where as some types of foods seem to increase PC risk 
(red meat, dairy products, and animal fat), others appear to offer protective benefits 
(lycopene, selenium, and Vitamin E).  
Prior published ecological studies have demonstrated strong correlations between 
PC development and consumption of dairy products, red meat, and animal fat. The 
positive correlation appears strongest with dairy products, with one study demonstrating a 
correlation of .69.102, 117, 118 Ecologic fallacy and confounding are possible explanations, 
but additional case-control and cohort studies seem to support this relationship, albeit not 
as strong.107, 109, 119, 120 Two hypothesized explanations of the relationship between PC 
and dairy products centers on the fat content and the high bio-availability of calcium in 
milk. The calcium hypothesis has gained support from a 1997 prospective study that 
evaluated dietary fat intake and PC risk. This study demonstrated that consuming 
increased amounts of fat-free and skim milk carried an increased risk of PC 
development.103  
The ‘Western diet’ has also been evaluated as a PC risk factor. It has been 
hypothesized that this diet (high intake of red meat, animal fat, dairy products, and 
protein) results in increased energy consumption, which can lead to increased levels of 
Testosterone, cell proliferation, and angiogenesis, with decreased cell differentiation and 
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apoptosis.104 This combination would lead to increased prostate growth, PIN, PC, and 
faster disease progression. However, epidemiologic studies have varied in their results. 
Where some studies have demonstrated increased PC risk, many others have reported no 
increased associated risk. 107, 109, 118, 119 
Although as a group, fruits and vegetables have not been associated with 
decreased PC risk profiles, certain vegetables have been supported as potentially 
protective.  Lycopene has been studied since the 1980s for its affect on PC risk. Many of 
the studies demonstrated reduced risks associated with high intake of Lycopene; however 
they were not statistically significant. One 1995 U.S. study, which evaluated 773 
subjects, demonstrated a statistically significant risk reduction (RR-0.65, 95 percent CI- 
0.44-0.95) when consuming greater than 10 dietary tomato-based products per week 
(compared to less than 1.5 servings). Although the data remains controversial, the 
increased consumption of tomato-based products (as well as fruits and vegetables) is 
recommended for cancer risk reduction and better overall general health. 
 Vasectomy 
 Prior epidemiologic studies looking at a possible link between PC and undergoing 
a vasectomy have failed to demonstrate consistent evidence of a causal association.111, 112 
This potential association has been under review for approximately twenty years. 
Although a number of studies have suggested there are increased risks of PC 
development associated with vasectomy surgery, many other studies have failed to 
demonstrate similar outcomes.113, 114, 115   
 In a 1992 retrospective cohort study looking at the incidence rates of cardiac 
arrest, testicular cancer, and prostate cancer in men who had underwent a vasectomy; no 
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evidence of increased PC risk was identified. Over 13,000 men who had a vasectomy 
were compared to 26,000 men who were hospitalized for elective operations, 
appendicitis, or injuries. The study reported a relative risk of 1.0, but noted longer periods 
of follow-up may be needed to study vasectomy effects on PC definitively.117   
An additional study from 1996 conducted in Puget Sound evaluated 175 men 
(who were status post vasectomy and recently diagnosed with histologically confirmed 
PC) with 258 controls. These controls were randomly selected from the general 
membership of the Puget Sound insurance group health plan. Conditional logistic 
regression analysis yielded an odds ratio for PC associated with vasectomy of 0.86 
percent (95 % confidence interval 0.57-1.32).112  
Skepticism remains over this suspected relationship, centering around two 
primary factors; biological plausibility and selection bias.111 The biological basis that 
attempts to explain the link between vasectomy surgery and increased PC risk has been 
questioned and remains speculative.113, 116 It has been shown that vasectomies result in a 
complete decrease of sperm, which in turn results in a decrease of total percent 
concentrations of prostate secretion and seminal vesicle hormones, while simultaneously 
increasing the level of sperm-antibodies.116 It is unknown if (and how) any of these 
biological changes results in increased PC development.116 
 In addition, selection bias remains a potential explanation for the previously 
demonstrated increased risk. Most vasectomies are performed by urologists, and most PC 
are diagnosed by urologists, therefore men who have undergone vasectomies are more 
likely to have their PC diagnosed.113     
 Additional research is needed in this area, specifically prospective cohort studies 
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and clinical trials. Moreover, previous studies have shown potentially increased risk in 
various sub-populations, therefore focus on those men at potentially increased risk prior 
to the vasectomy should deserve particular acute focus. 
Alcohol 
 Alcohol consumption effect hormones by transiently depressing circulating 
testosterone levels (in men) and increasing estrogen levels (in women).119 Alcoholic 
cirrhosis has also been shown to depress circulating testosterone levels.120 There has been 
significant interest in a possible link between alcohol use and PC development.121 
 Alcohol consumption is a prevalent life-style activity and is modifiable, therefore 
the identification of a causal relationship with PC would have a significant impact on 
public health.119 Prospective and retrospective reviews have been performed on the 
potential relationship between alcohol consumption and PC and has found limited 
evidence to support a causal association.119 There has been greater than 30 studies 
investigating this potential link over the last 30 years.119  
 A 1996 study looking at PC risks in relation to alcohol intake in U.S. African-
Americans and whites demonstrated a significant association (RR 1.8, 95% CI 1.1-3.0) 
with high grade PC and heavy alcohol intake (greater than 57 drinks per week). When the 
PC outcome was evaluated as a binary outcome, the relative risk was not significantly 
increased. Moreover, follow-up studies have not found similar results.118  
A European study, looking at the influence alcohol plays on PC, found a gradient 
association between total grams of alcohol consumption and PC development in Swedish 
men. However, their results were not statistically significant, thus the apparent 
relationship could have occurred by chance.125  
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In a review of all previously published literature that summarized issues of 
causation, no compelling evidence of a causal link between low-to-moderate alcohol use 
and PC was observed.119 The authors recommended targeted research focused on select 
subsets of men including heavy alcohol consumers. In addition, they recommended 
population prospective studies, as well as increased attention on genetic markers of 
patients with familial risks.119  
Vitamin A 
 Prior research on cancer incidence suggests increased consumption of vitamin A 
can be a protective dietary practice.125 However research on the association between 
vitamin A and PC has hinted that a more complex relationship may exist. There have 
been published studies that have attributed both protective and causal effects associated 
with increased vitamin A intake on PC developement.125-129  
The National Health and Nutritional Examination Survey I Epidemiologic 
Follow-up Study followed over 2,440 men (> 50 years old) for an average of 10 years 
and found mean levels of serum vitamin A were lower in men who developed PC when 
compared to men who did not develop PC.126 These results were statistically significant 
and were evaluated as both a continuous and ordinal variable.126 After adjusting for age 
and ethnicity, the researchers found that men in the lowest quartile of vitamin A intake 
had a RR of  2.2 (95% CI  1.1-4.3) when compared to men in the highest quartile. The 
increased risk of PC development did not weaken with increasing time between serum 
draw and diagnosis.126 In addition; similar protective findings were also reported between 
vitamin A intake and PC in a case-control study published in 1988.127  
In 1989, dietary and lifestyle characteristics of approximately 14,000 Seventh-day 
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Adventist men were obtained for comparison with subsequent PC development.128 Each 
study subject completed detailed questionnaires on a variety of lifestyle factors, including 
information on foods known to be high in vitamin A. Consumption information was 
obtained on the following specific foods: green salads, citrus fruits, and tomatoes.128  The 
researchers utilized Cox proportional hazards regression models for statistical analysis 
and found men that consumed foods that are known to contain increased levels of vitamin 
A had a decreased risk of PC development (See Table 3 below).   
Fruit and Vegetable 
Consumed 
Relative Risk 95% CI 
Green Salad (>= 1x/Day) 0.68 (0.44-1.05) 
Fresh Citrus fruit (>= 
5x/Week) 
0.53 (0.34-0.86) 
Tomatoes (>= 5x/Week) 0.57 (0.35-0.93) 
Table 3. Age-Adjusted Relative Risk for PC by Fruit and Vegetable Consumption 
(Mills, Beeson, Phillips, and Fraser, 1989). 
 One study that demonstrated conflicting findings was a retrospective, case-
control study, which was performed in Hawaii on 1,351 men (452 PC positive, 899 
population controls). All men within the study provided detailed dietary histories between 
the years of 1977-1983. The men were stratified on age (< 70 or >= 70 years), and 
controlling for differences in ethnicity was performed.126 The researchers found that men 
70 years or older strata, who were in the highest quartile of vitamin A consumption 
group, had a  statistically significant odds ratio of 2 when compared to the lowest 
consumption group.126  
Two additional published studies demonstrated larger risks of PC development 
with increased consumption of vitamin A. A study by Graham, et al., found the relative 
risk of PC increased in a gradient fashion as vitamin A increased. This trend was more 
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apparent in men 70 years or older.129 Hershmat, et al., described a similar relationship in 
a case-control study that was published in 1985, although the odds of PC development 
was strongest in younger men (less than 50 years of age).130  
Many explanations have been hypothesized as to these conflicting results. The 
differences may be a result of inherent difficulties of capturing data on diet, as well as 
separating vitamin A from other carotenoid and retinoid compounds. Additionally, the 
majority of the retrospective analyses have lacked large case numbers and as a result the 
powers of these studies remain in question.   
Other Micronutrients  
 The antioxidant, vitamin E, has been evaluated as a possible protective agent in 
cancer genesis due to its reported anti-cancer properties.999 It is previously been 
suggested that vitamin E may impede the development of cancer by inducing apoptosis in 
cells with altered or damaged DNA.105 There is limited epidemiologic studies on the 
possible relationship between vitamin E and PC, however.  
A randomized prospective study published in 1998 demonstrated a protective 
effect with vitamin E use. In the study, men were either randomly assigned to receive 
either a placebo or vitamin E supplementation in their diets. The men that received the 
vitamin E had a reduction in their PC incidence of greater than 30 percent, and the 
mortality second to PC decreased by greater than 40 percent.120 In a more recent 
evaluation of the potential protective effects of vitamin E, 1,896 physicians were tracked 
prospectively in the Health Professionals Follow-up study. Augmentation of diets with 
vitamin E did not result in a lowering of the risk of PC development. This particular 
study enhanced the accuracy of the vitamin E measurement by documenting intake twice 
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per year, and also had increased power when compared to the previous (1998) study.121  
However, a protective effect was seen after stratifying on smoking status and 
looking only at the aggressive PC cases. The ex-smokers had a relative risk of 0.51 (95% 
CI 0.26-0.98) when compared to never smokers. The authors recommended further study 
of vitamin E, in particular the potential effect modifying relationship seen with smokers. 
Prospective studies exploring this relationship are ongoing. 
Vitamin D has been evaluated for over 10 years to discern the exact role it plays 
in prostate cancer genesis. Molecular studies have demonstrated that vitamin D receptors 
are present on prostate epithelial cells and PC cell lines.131 These receptors are thought to 
increase the expression of androgen receptors and PSA androgen-regulated genes. 
A 1990 study that evaluated vitamin D as a risk factor for PC development 
reported that patients with low serum vitamin D levels had a significant relationship with 
ethnicity, age, and geographic location, frequently cited PC risk factors. A second 
epidemiological study demonstrated that decreased serum vitamin D levels (Ca2 less than 
8mg/dl) was associated with increased risk of high-grade tumors and advanced stage 
disease.132   
Clinical trials of vitamin D and its analogs are underway currently and although 
hypercalcemia was a frequent complication, it is believed that these compounds can 
reduce any PC prompting activity currently seen with varying vitamin D serum levels.     
Obesity 
 Previously published case-control studies suggested that obesity increases the risk 
of PC development.99, 107, 109, 110 Ecological studies have demonstrated strong correlations 
between obesity and increased risk of PC development.99-, 107, 109 However, given certain 
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methodological issues, this relationship has been questioned. In many studies, the 
utilization of only height and weight was utilized to assess body mass.107 Moreover, 
consistency between retrospective and prospective studies have been lacking. As a result, 
it is unclear if obesity is a causal exposure for PC development.  
 The first study that published findings suggestive of a causal association between 
increasing body mass and PC was a hospital based case-control study out of Northern 
Italy.110 The researchers reported that increased PC risks existed in obese men (when 
compared to men of the expected body mass). Limitations of this study included the 
utilization of hospital based controls, and determining body mass strictly on the basis of 
height and weight.110 
To correct for this limitation, a prospective study published in 1988 evaluated the 
influence that body mass had on PC development with the utilization of several body 
measurements.52 The authors initiated a more detailed assessment of the subjects to 
delineate increased body mass secondary to muscle verses adipose tissue. They calculated 
Incidence Density Ratios (IDR) on 7,820 men, comparing a multitude of different body 
measurements. The researchers reported that the risk of PC was not significantly related 
to BMI, skinfold thickness, height, or leg length.52 They did note that the RR was 
significantly increased with girth in the upper arm and weight in kilograms, although this 
relationship did not demonstrate a linear trend.52 The authors concluded that their results 
were preliminary and that it appears the risk of PC increases with increasing muscle mass 
and not necessarily with adipose tissue weight gain.52
In a study published in 1971, Wynder et al. retrospectively evaluated 1,050 
patients to better determine the epidemiologic factors of prostate cancer and review 
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certain factors believed to be associated with PC development.51 The review looked at 
300 subjects who were diagnosed with PC, 400 controls, and the charts of 350 additional 
patients who had PC.51 Two factors that were evaluated closely included weight and 
height. The authors found no significant difference in the height and weight of the PC 
subjects when compared to the controls. In fact, a higher percentage of control patients 
were overweight than the PC patients.51     
In addition, a 1984 prospective study noted increased PC risks for overweight 
men.59 The study evaluated a cohort of 6,763 white male Seventh-day Adventists who 
had completed a dietary questionnaire in 1960.107 They were followed-up to assess the 
effects obesity played on the risk of fatal PC development. They authors reported that 
men who were overweight had a significant RR of 2.4 (95% CI 1.3-4.5) for fatal PC 
development, when compared to men within the referent group.107 Although this study 
provides compelling statistics, the study utilized basic measures of diet, as well as basic 
measures of body mass. In addition, since the studies endpoint was fatal PC, it is unclear 
whether the disparities in types of food intake resulted in increased death secondary to the 
PC or a competing cause of death. In addition, the issue of inaccurate cause of death 
determination on the death certificates cannot be discounted. 
Although there appears to be some evidence of a causal relationship between 
obesity and PC, difficulties with methodological issues (and a lack of prospective studies) 
has hampered the understanding of this complex relationship. As a result, any assertion 
that obesity can increase a subject’s risk of PC development is purely speculative.    
Circulating Testosterone 
 Testosterone is an essential androgen hormone that is vital for the healthy, normal 
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development of male reproductive organs. It is believed to be responsible for 
spermatogenesis and the regulation of gonadotropic secretion.31 In addition; testosterone 
is a common treatment for hypogonadism, and is used as a palliative therapy for breast 
cancer.31  
 For decades, many researchers and clinicians have hypothesized that increased 
levels of circulating testosterone is a risk factor for PC development. However, the 
plausibility of this causal relationship has been questioned, given that PC is dependent on 
continued availability of androgens, and androgen levels decrease as a man ages.109 The 
decreasement of circulating testosterone has been a PC treatment strategy for many 
years.108 The complete understanding of this complex relationship has proven to achieve. 
Difficulties in evaluating testosterone levels and methodological limitations in previous 
studies designs has been cited as limiting factos.109 For instance, many of the published 
studies have utilized blood samples that were taken after the diagnosis of PC, thus 
concerns over the temporality of the relationship exist. In addition, many of the previous 
studies have limited sample size, or non-representative control groups.108
 However, a study out of Canada evaluated the relationship between Serum 
testosterone and dihydrotestosterone with PC on 75 (33 PC patients, 42 controls) 
otherwise healthy men. The noted the mean value of serum testosterone for the control 
group was 16.74 (95%CI 17.5, 15.98), while the PC patients was 20.94 (95%CI 22.42, 
19.46). The results were statistically significant, however the researchers stated that the 
wide range in values seen in the PC patients limits the practical value of the biomarker, 
and further study by a prospective approach would be necessary. 
In 1996 a prospective study was performed, investigating whether plasma 
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testosterone and sex hormone-binding globulin levels in men were related to the 
subsequent development of PC.107 The researchers utilized a prospective, nested case-
control approach, looking at the participants of the Physicians’ Health Study who 
provided blood samples for future evaluation. There were 222 participants who 
subsequently developed PC after the study began. Three hundred-ninety controls were 
matched on age, smoking status, and length of follow-up. Logistical regression modeling 
was used to determine the Odds Ratio specifying the risk associated with increasing 
hormone levels. High levels of circulating testosterone demonstrated a association with 
PC as levels of plasma testosterone increased.107 For increasing quartiles of plasma 
testosterone, the OR were as follows: 1.00, 1.41, 1.98, and 2.60.107 The confidence 
intervals were statistically significant, and the researchers concluded that high levels of 
circulating testosterone were likely associated with PC.  
History of STD and Other Sexual/Reproductive Factors 
 Age at first sexual intercourse, intercourse frequency, history of Sexual 
Transmitted Diseases (STD), and the number of sexual partners have all be evaluated as 
potential risk factors for the subsequent development of PC. It has been hypothesized that 
PC may be caused by the transmission by an infectious agent through sexual activity.112 
However a cohort study of cancer mortality demonstrated an excess of PC deaths in 
Catholic priests, which points away from an STD etiology.113 The results of the 
subsequent follow-up studies have failed to demonstrate a clear causal pathway.  
 The most thorough evaluation of these potential causal exposures was performed 
in California in the late 1970s. This population-based, case-control study was performed 
on 221 men who were identified by the Los Angeles county cancer surveillance program 
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as having histologically diagnosed prostate adenocarcinoma. Cases were restricted to 
white, non-Spanish sir names, and each case was assigned a similar neighborhood 
control. Both the cases and control were interviewed over the phone using a structured 
format by a single trained interviewer. The researchers reported that the risk of PC 
development were higher in men with earlier age at first sexual intercourse (age <17 vs. 
21+, RR = 2.3, 95% CI 1.3-4.0), but there was no association with the number of sexual 
partners or the frequency of sexual intercourse.112 Moreover, there was not a significant 
relationship with STD history, although the small number of cases limits the 
interpretation of the results.  
Socio Economic Status 
 The relationship between socio economic status (SES) and PC incidence has been 
evaluated since the 1950s. At that time, literature suggested that the increased PC 
incidence seen in African-American men could be related to lower SES.107 However, 
follow-up studies that have evaluated education, income, and residence zip code (with PC 
development), failed to demonstrate consistent evidence to support this hypothesis. In a 
1971 study of PC modifiable risk factors, the relationship between education attainment 
and PC development was analyzed separately for both Caucasian and African-American 
men.108 For Caucasian men, there was no significant difference between rates of PC 
incidence and the different education categories (stratified as ‘no school attendance’; 
‘grammar school’; ‘high school’; and ‘college’). African-American men who had 
attended grammar school or less had a 14 % increased risk of PC development. However, 
due to small sample size, the results were not statistically significant.  
In 1972, a study in California again revisited socio economic status and its 
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relationship to PC incidence and mortality. This case-control study compared PC 
incidence data from the Alameda county cancer registry and death certificates data with 
the average income for the Alameda residence zip codes. The researchers found that after 
stratifying on ethnicity, African-American men maintained their increased incidence rates 
(compared to Caucasian men), despite the increased education. However, the study did 
not report the statistical significance of their findings.  
Occupational Studies 
 There is mounting evidence that suggests there exists an inverse relationship 
between certain types of cancers and occupational activity.123 In particular, diverse 
populations have been studied in relation to job-related activity and their risk of colon 
cancer, and there is a consistent association between occupational physical activity level, 
recreational physical activity level, and colon cancer risk.123  The specific relative risks 
has varied between the studies, with one study demonstrating no apparent association, 
while other epidemiological studies report risks between 20-100 percent, respectively.122
 In a 1991 Missouri case-control study, the odds of white men being diagnosed 
with prostate cancer were increased if they had low or moderate activity levels at work.122 
This study was initiated to evaluate cancers in relation to occupational activities. The OR 
of a white male worker developing PC was 1.1 (95% CI 1.0-1.3) for men with moderate 
activity, and 1.5 (95% CI 1.2-1.8) for men with low activity levels (compared to the 
reference group; high activity).122 The odds ratio for low activity level was statistically 
significant, and the researchers controlled for age and smoking status. The authors 
concluded that their results should be considered preliminary and require confirmation 
with other studies.122
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 In a study published in 1987, which looked at the relationship between 
occupational activity and the incidence of cancer (including PC), it was reported that 
longshoreman with decreased occupational activity levels had increased odds of PC 
development (when compared to longshoremen with increased activity levels).124 This 
study was performed in San Francisco, California, and did have certain limitations. These 
limitations included a lack of controlling for Social Economic Status (SES), and had a 
vague surrogate marker for physical activity.124      
 The biological mechanism that links physical activity levels and PC development 
remains unclear. Researchers and clinicians have hypothesized that the relationship may 
be bound by a decrease in the cancer growth promotion factors as a result of the physical 
exertion.122 This may be so, but it has been proven difficult to discern exactly how much 
physical activity is required, and for what duration, for the protective effects to be 
realized. A better measure of job related activity, randomized clinical trials, and 
prospective studies are required to answer this question with more clarity. 
Tobacco  
 The use of tobacco products (specifically cigarette smoking) has been evaluated 
as an exposure that increases the risk of developing prostate cancer. However, the results 
of previous studies evaluating this relationship have been unclear. A slightly increased 
risk has been identified; however it has not been consistently demonstrated and 
researchers are unsure if this relationship was actually due to the biological effect of the 
tobacco smoking, or secondary to delayed diagnosis and treatment.94  
 Different pathways have been hypothesized on how tobacco could induce PC. 
One revolves around the tobacco use prompting a more ‘aggressive’ phenotype that 
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progressives more quickly and is more fatal. A second hypothesized pathway centers on 
the concept of ‘hormone alteration’, either resulting in the hormones prompting cancer 
growth, or turning off the tumor impeding genes.95  
Conclusion/Assessment of the Literature 
 There exists a gap in the literature addressing PSA as a prostate cancer screening 
tool. Earlier PSA research by Catalona, the U.S. Preventive Task Force, (and more recent 
work by Thompson, Carter, the PLCO, and others) have been critical in improving our 
ability to identify prostate cancer at earlier disease stages. However, there is continued 
debate on whether (or not) PSA remains the best currently available tool for the detection 
of pre-clinical PC. This debate is likely to continue until the results of the PLCO trial are 
released (tentatively scheduled for 2014). There seems to be little debate over the 
limitations PSA possesses as a PC screening tool. Undoubtedly, a strength to prior peer-
reviewed published literature has been the consistent demonstration that, since the 
inception of PC screening on a national level, the utilization of a single PSA draw (with 
or without DRE) as the prompting factor for prostate biopsy referral has resulted in 
millions of unnecessary (non-risk free) prostate biopsies.5, 22 An overt weakness of the 
prior published studies has been the lack of easy to implement solutions to this complex 
problem.  
 How can PC screening be improved upon? Despite a wealth of published 
literature that has evaluated PSA and argued against its use as a PC screening tool, PSA 
remains the mainstay for clinicians for PC screening. Thus, the focus must be on 
augmenting PSA, not replacing it all together. Prior attempts at improving PC screening 
have focused on replacing PSA with a new test. Tools such as PSA velocity, PSA 
 55 
density, Free/Total PSA ratio, and newer assays have all shown promise in studies for 
improving PC screening results, but difficult implementation and a lack of universal 
acceptance among clinicians have hindered their incorporation into daily clinical 
practice.7, 23, 26, 27, 40, 41, 41, 86  
 Has researchers and clinicians made the most of all available information 
when evaluating a patient for prostate cancer? Routinely ordered lab panels (complete 
blood counts (CBC), basic metabolic panels (BMP), and urinalysis (UA)); all contain 
biomarkers that change in value when diseases associated with prostate cancer are 
present. Yet these biomarkers have been in essence ‘ignored’ when evaluating a patient 
for PC.  
Many previous studies have accurately described PSA elevations as ‘specific to a 
condition of the prostate’. However, in what must be considered a weakness of the 
literature, there has been a lack of clarity in describing that the aforementioned PSA 
elevations are not specific to prostate cancer. In what may hold the key to improving the 
overall yield of PC screening, evaluating changes in certain laboratory biomarkers values 
that (in the presence of an elevated PSA) are associated with diseases that are a product 
(directly or indirectly) of PC spread may provide a wealth of important information that 
can improve of ability to accurately predict PC presence in patients undergoing PC 
screening.  
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Chapter III -Methods  
The overall goal of this study is to improve the efficiency of prostate cancer 
screening through the development of a clinical decision rule that is based on an elevated 
PSA and a predictive set of clinical biomarkers. The study is a cross-sectional study, 
evaluating men from the James A. Haley VA hospital from January 1, 1998 through April 
15, 2005. The men are between 40-90 years of age, prior military servicemen, who utilize 
the Tampa VA medical network for at least some of their health care needs. All men have 
all undergone prostate biopsy. The subjects are classified into one of four ‘histology’ 
groups. The cases consist of biopsy confirmed prostate cancer. There are 3 control 
groups: (1) biopsy confirmed Prostatic Interstitial Neoplasm (PIN), (2) biopsy confirmed 
Benign Prostatic Hypertrophy (BPH), or (3) biopsy confirmed prostatitis, to answer three 
primary questions of interest (see below). 
1 - Aims/Hypothesis  
   Aim 1: The first aim is to identify biomarkers that are both related to prostate 
cancer and have the capability of improving the efficiency of PC screening. Within the 
biopsied groups of men, evaluation of routinely ordered laboratory biomarkers 
(hematologic, serologic, and urologic) will be performed to assess for statistically 
significant relationships between the biomarkers and disease status. It is known that PSA 
values can be elevated due to many prostate conditions, however it is believed to be 
unlikely that the non-cancerous conditions that elevate PSA would also cause changes to 
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other body systems (represented by the lab biomarkers). In prior published research, 
advanced prostate cancer has been indisputably identified as a cause for such laboratory 
changes.34 In a 1997 study; anemia was a frequent complication of advanced prostate 
cancer. The two primary types of anemias identified with PC are Iron Deficiency Anemia 
(a subset of microcytic anemia), and anemia of chronic disease (either 
normocytic/microcytic anemia). The etiology of anemia in prostate cancer patients is due 
to the cancer itself, the therapy for the cancer, or unrelated conditions.34 Currently; there 
is a paucity of documented research assessing the impact of cancer related anemias on 
cancer screening.32  
Hypothesis 1: Among VA patients who have undergone prostate biopsies secondary 
to a PSA value of >4ng/dL, specified lab biomarkers* among cases of prostate 
cancer will differ significantly from those among VA patients without prostate 
cancer.      
Aim 2: Upon completion of the above aim, sets of orthogonal biomarkers will be 
developed to determine which can best predict the presence of prostate cancer. These 
potential screening sets will be compared to the current screening tool (PSA only), to 
evaluate for improved effectiveness in prostate cancer detection. The inclusion of 
additional predictors offers potential for decreasing false positive tests, resulting in 
increased specificity, predictive values, and better overall validity.  
 Hypothesis 2: Among VA patients who have undergone prostate biopsies secondary 
to a PSA value of >4ng/dL, the addition of specified lab biomarkers* will improve 
the effectiveness of predicting the presence of prostate cancer when compared to 
PSA alone. 
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An essential goal of this study is to increase the identification of PC that has the 
potential to threaten life. This PC has not yet afflicted serious morbidity and mortality, 
but will if untreated. Therefore, perhaps the most important cases of prostate cancer to 
identify through screening are stage A and B which have aggressive grade scores.   
 Many stage A (low grade), indolent prostate cancers are unlikely to become 
clinically evident, and their identification through PC screening is not of paramount 
importance.10, 16 Prostate cancers that contain aggressive properties would (theoretically) 
demonstrate evidence of both prostate activity (verified through elevated PSA), and 
systemic evidence of cancer (verified through lab biomarker changes). It has been 
previously established that PSA values can be elevated due to a multitude of prostate 
conditions.41, 87 However, it is considered unlikely that non-cancerous prostate conditions 
will cause changes to other body systems (represented by the lab biomarkers). Moreover, 
indolent cancers are believed to be unlikely to cause an identifiable biological change, 
and the PC that has overtly traversed the prostates borders will typically demonstrate 
clinical symptoms (urinary obstruction, bone pain, weight loss, etc.), thus more likely to 
be diagnosed in the clinical setting. 
Aim 3: The third aim of this study is to assess for a dose-response relationship 
between specified lab biomarkers (surrogates for extra-prostatic disease development) 
and the progression of prostate cancer. If present, this parallel progression will 
demonstrate the presence of a gradient between prostate cancer and systemic disease.  
Hypothesis 3:  Among VA cases of histologically confirmed prostate cancer, there 
exists a gradient between specified lab biomarkers* and increasing stage of prostate 
cancer. 
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2 - Participant Description 
Participants are men who have undergone prostate biopsy within the VA 
Healthcare networks located in Tampa, Florida. The demographic characteristics of the 
population under study are as follows: The James A. Haley VA group are primarily 
Caucasian middle-aged veterans (mean=68 y/o, SD=12) with an education attainment 
level of at least four years of high school, or some college attendance.37 When the 
education of veterans is compared to that of non-veterans on a national level, significant 
differences exist. For instance, 12 percent of veterans had not graduated from high 
school, compared to 18 percent of non-veterans. Moreover, 65 percent of veterans have 
completed high school or have attended 1 to 3 years of college, compared to 56 percent 
of non-veterans.  Lastly, when comparing the rates of completing 4 or more years of 
college, non-veterans are more likely to have accomplished this feat (26 percent 
compared to 23 percent).    
Data suggest that upwards of 2.5 million individuals receive all or part of their 
healthcare needs from the VA medical system.37 The Florida VA healthcare network 
handles on average a total of 1,718,528 male patient encounters each year.37 This total 
represents approximately 6 percent of all the male visits within the National VA system. 
The following table (Table 4) stratifies these numbers by age specific groups: 
State Age 50-54 Age  55-59 Age  60-64 Age  65-69 
Florida 155, 611 198, 258  147, 565  164,481 
Table 4. Summary of age distributions: male patient visits (Florida VA, 2001). Data 
Source: VA Department, National Survey of Veterans. 
 
The VA and census data estimate that as of 30 September, 2004, approximately 
 60 
93,500 men in Hillsborough County (Tampa, Florida) are eligible to receive healthcare 
services at the James Haley VA hospital. Additional demographic data reveal veterans 
compare closely to their non-veteran counterparts on several measures of socioeconomic 
status; including personal income, and health insurance coverage.38 However, users of 
VA inpatient and outpatient care have less health insurance coverage than veterans in 
general.38 Approximately 9 percent of all veterans were uninsured in 1993, compared to 
21 percent of veterans who used their VA medical benefits. This holds true for veterans 
under the age of 65, as 13 percent did not have health insurance, compared to 29 percent 
of those veterans that used the VA healthcare system.38
Inclusion criteria: 
    1. All patients with a PSA value of 4ng/dL (or higher) with a history of prostate 
biopsy (TURP and/or core biopsies and/or prostatectomy) dated between January 1, 1998 
until April 15, 2005.    
2. Additional laboratory data (obtained at the time of PSA sample): 
 
Hematology: 
Red Blood Count (RBC) 
Hemoglobin 
Mean Corpuscular Volume 
(MCV) 
Platelet count 
White blood count (WBC) 
PT/aPTT 
Chemistry: 
Albumin 
Urea Nitrogen (BUN) 
Creatinine 
Bilirubin-Direct/Indirect 
Lactate Dehydrogenase 
Total Protein 
 
Urinalysis: 
Hematuria 
Proteinuria 
 
Table 5. Laboratory Biomarkers 
                         
 3. Males age 40 to 95 at time of initial diagnosis of PC, PIN, BPH, or prostatitis. 
Exclusion criteria: 
        1. History of prior genital urinary malignancy. 
 2. Individuals for whom pathology report states that the biopsy specimen is 
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inadequate. 
3 - Design  
The design for this investigation is a cross-sectional study. The subjects are 
classified into one of four ‘histology’ groups. The cases consist of biopsy confirmed 
prostate cancer. The controls consist of 3 groups; biopsy confirmed PIN, BPH, or 
prostatitis. 
4 - Case Identification 
A diagnosis of PC is based upon a set of standard procedures for both the clinical 
decision making process and the biopsy of the prostate.  Upon identification of an 
elevated PSA lab test (with or without the identification of a prostate nodule during 
physical examination or transrectal ultrasound), the patient undergoes a prostate biopsy 
that is then sent to the pathology department for histological determination. For quality 
control purposes, random case review is performed monthly by local VA pathologists, 
and external quality control is assured by 10 percent random case review by pathologists 
assigned to the Armed Forces Institute of Pathology, located in Washington, DC.  
5 – Data Collection Methods 
A case of prostate cancer is defined by prostate tissue that demonstrates cells of 
adenocarcinoma on histologic evaluation.4 With that, identification of potential study 
subjects was accomplished through utilizing the search option in the Anatomic Pathology 
portion of VISTA (SNOMED finalized accession logs) to find all cases coded as 'prostate 
disease' (SNOMED codes: 77220, 77103, 77102, 77101, 77110, 77105, 77350, 77230, 
77210, 77300, 77200, 77240, 77104, 77100, 77000, 77900, 77250). The patient’s 
identification number, date of the specimen, diagnosis text code, and accompanying 
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narrative text description were captured through this VISTA search. The SNOMED 
system (Systematized Nomenclature of Medicine) is a division of the College of 
American Pathologists, and is the standard tool used by pathologists to create, share, and 
retrieve pathology information.125 The SNOMED system is used by the James Haley VA 
hospital for aggregating all pathology data. The collection of both the diagnosis text code 
and accompanying text description was performed intentionally as a way to validate the 
histologic diagnosis. For instance, if the diagnosis code was ‘adenocarcinoma of the 
prostate’ (SNOMED code 77220); the corresponding narrative text description would 
provide the same diagnosis. The goal of this initial search was to capture all prostate 
related cases; hence the abundant amount of SNOMED codes used. At this point there 
were 2,575 unique patient identifiers that could be potentially associated with prostate 
cancer.  
The James Haley VA electronic medical records (EMR) were then accessed for 
all of the identified potential PC cases to validate the diagnosis (by identifying PC ICD-9 
codes or ‘PC’ stated as the assessment in the narrative dictation) and capture additional 
data relevant to this study. Demographic data (age, ethnicity), laboratory biomarkers, and 
any previous pathology results were captured through the review of surgical operative 
reports, progress notes, medication logs, admitting summaries, and discharge dictation 
summaries. This data was still grouped within the Vista system, and to development a 
relational database, it was exported to the Microsoft Access system for further dataset 
development. (A relational database is required to match data from different datasets for 
each individual).  
Upon satisfactory export of the above data, a relational database was created to 
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link the different data sources. Multiple Access tables, queries, and forms were created. 
In particular, the following 7 different tables were created in Access: histologic diagnosis 
codes, narrative histologic dictation notes, inpatient diagnosis codes, demographics 
(gender, age at biopsy, race, and ethnicity), laboratory biomarkers of interest, date of 
biopsy (with age at biopsy), and ICD-9 codes for all previous diagnosis (within the JH 
VA) recorded for each patient.  
Access forms were then created as a tool to create new diagnosis categories. In 
particular, new data elements were created that categorized each prostate biopsy as PC, 
PIN, BPH, or prostatitis. Each biopsy diagnosis text code and accompanying text 
descriptions were reviewed closely to reduce the probability of misclassification of the 
study outcome (histologic evaluation of adequate prostate tissue). 
    A second Access form was created for capturing both the PC stage and Gleason 
score for each patient with a histologic diagnosis of PC. The stage was categorized as 
follows: stage A for non-palpable, prostate contained cancer; stage B for palpable, 
prostate contained cancer; stage C for locally spread PC; and stage D for metastatic PC.  
To determine the Gleason score, the two most prominent areas of PC activity (as 
identified by the evaluating pathologist on histologic examination) were identified. Each 
prominent area was given a score of 1-5, with 1 being well differentiated, and 5 being 
poorly differentiated (implying a more aggressive appearance). The two scores are added 
together, and this number was the recorded Gleason score for all subsequent analysis. 
Upon establishing each subject’s new diagnosis category (which is to be used as 
the primary outcome variable of this study) and Gleason score, these variables (as well as 
laboratory and demographic data) were exported into Microsoft Excel for continued 
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dataset development. After successful export of the above mentioned data into Microsoft 
Excel, attention was given to determining the accurate ethnicity of each potential study 
subject. Initially, both the race and ethnicity fields (within the histology text description 
reports) were screened for ethnicity key words (e.g. Caucasian, African American, white, 
black, etc.). However, more than 60 percent of these fields were left blank; therefore 
addition capture techniques were employed.  
For the 40 percent of the potential study population that did not have race or 
ethnicity captured within the prostate biopsy histology text description reports, evaluation 
of (EMR accessible) previous surgical operative reports, outpatient progress notes, 
emergency room notes, admitting hospital summaries, and discharge dictation summaries 
were reviewed, looking for any mention of race and or ethnicity. Screening for 
commonly used medical short-hand information (e.g. 67 y/o aam; “67 year old African 
American male”) was also performed, which ultimately left only 6.6 % (170/2575) of the 
potential subjects with “unknown/refused” as their ethnicity designation. 
For accurate determination of each subject’s age, the age was calculated by 
subtracting the birth date from the date of prostate disease determination. The age of non-
cancer subjects was established by subtracting birth date from the date of histologic 
evaluation.  
    To aggregate the specific laboratory biomarkers of interest in this study, an MS 
Excel table was created that contained all laboratory samples obtained from each 
potential study subject within the studies time frame. After successful creation of the 
table, lab values that were not of interest in this study were then deleted. The below tables 
details the laboratory biomarkers of interest: 
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Hematology: 
Red Blood Count (RBC) 
Hemoglobin 
Mean Corpuscular Volume 
(MCV) 
Platelet count 
White blood count (WBC) 
PT/aPTT 
Chemistry: 
Albumin 
Urea Nitrogen (BUN) 
Creatinine 
Bilirubin-Direct/Indirect 
Lactate Dehydrogenase 
Total Protein 
 
Urinalysis: 
Hematuria 
Proteinuria 
 
Table 6. Laboratory Biomarkers 
Subsequent to deleting the extraneous lab biomarkers, attention was given to the 
specific date of the lab biomarker sample. Inclusion criteria for this study state that the 
lab biomarker sample was to be obtained at the time of PSA sample; therefore PSA and 
biomarker sample dates were compared to ensure time consistency. If the lab biomarkers 
were not obtained at the same time as the PSA draw, they were deleted from the table 
(Inclusion criteria). 
 After performing the above mentioned activities, an aggregate table was created 
in MS Excel that contained the following information on each of the 2,575 potential 
study subjects: patient ID number, age, histology category (PC, PIN. BPH, prostatitis), 
PC stage (A, B, C, D), Gleason score (if PC positive), ethnicity (Caucasian, African-
American, Hispanic, Other), and the above lab biomarkers. This table was then utilized as 
the base dataset for all subsequent data analysis, to include the below data reduction 
strategies.   
Data Reduction Strategies 
 
 Upon developing the base dataset for the data analysis portion of this study, data 
reduction strategies were employed which ultimately left 1,378 participants available 
(form 2,575 potential subjects) for statistical analysis. Over 500 prostate biopsies (541) 
did not meet inclusion criteria because they where performed on men who did not have a 
 66 
PSA test value of 4.0 ng/dl or greater. Typical situations that would result in this scenario 
includes men who had biopsies secondary to a suspicious DRE or TRUS, or  biopsies 
secondary to other reasons (e.g. patient request due to family history). There were 321 
biopsies identified as “repeat biopsies”, which were then dropped from the study. Next, 
prostate biopsies that were performed as a result of other genital urinary malignancies 
(i.e. bladder, renal, ureter, and penile cancer) (N=260) were excluded. It is important to 
note that the specific prompting for all prostate biopsies was confirmed through a detailed 
record review of each prostate biopsy report within the VISTA system. These notes were 
in narrative form and were validated by confirming the ICD-9 code for that event. Lastly, 
participants without a full complement of laboratory biomarkers were excluded from the 
study (N=75). At the completion of the above mentioned data reduction strategies, 1,378 
participants were analyzed in this study. Figure 1 below is a schematic of the studies data 
reduction process.  
 Figure 1.  – Data reduction strategy. 
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6 - Statistical Procedures 
Univariate, bivariate, logistical regression, linear regression, and receiver operator 
characteristic curves were utilized to address the primary and secondary questions of 
interest. All models were risk adjusted for ethnicity and age.  
All data was abstracted from the VA hospital medical and laboratory records 
computer system (VISTA). It was then entered into MS EXCEL for data verification and 
review (See above for detailed explanation). Data was then imported into the SAS 
statistical software program and univariate analysis was initiated. The use of this 
descriptive analysis process allowed for careful review of data frequencies, measures of 
central tendency, and distribution shapes. Additionally, identification of out of range 
data, determination of the quantity of missing data, and accurate description of the study 
population was achieved by utilizing this process.  
Upon completion of the descriptive analysis, bivariate analysis was performed. 
Bivariate analysis allows for testing of hypothesis 1 (see above), to determine the 
statistical significance and degree of correlation between the independent variables under 
review and the presence of prostate cancer.  
Multivariate logistical regression was utilized to evaluate hypotheses 1 and 2. 
Regression techniques were used to identify linear mathematical equations which best 
described the relationship between the presence of PC and the independent predictor 
variables. Regression diagnostic techniques were employed to increase the likelihood of 
obtaining statistically sound and reliable analysis results. Binomial logistic regression 
was also utilized, given the outcome variable (prostate disease status) was coded as a two 
category outcome (PC yes= 1, PC no = 0). 
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A complete model (including age, ethnicity, biomarkers, and any interaction 
terms) was established initially. Exclusion of each covariate, one by one, was performed, 
looking for a change in the overall – 2 Log Likelihood Ratio. A potential covariate was 
permanently removed from the model development process if there was no effect on the 
overall – 2 Log Likelihood value. This lack of change indicates the specific variable is 
not contributing to the prediction of the outcome, and conversely, if there was a change 
of statistical significance, the variable was included in the final model. Additionally, 
interaction between covariates was assessed by creating combination variables, which 
assessed for additive and multiplicative effects. To test the significant difference between 
the full model and the final model, evaluation of the likelihood ratio p-value was 
performed, in which a value greater than 0.05 indicated a satisfactory fit of the smaller 
model. 
Receiver operating characteristic (ROC) curves were employed to address the 
second hypothesis. ROC curves are graphical tools which plots the sensitivity vs. 1- the 
specificity for a binary classification system (as a function of changes in the cut-off value 
threshold).39 This analysis technique was utilized to demonstrate the difference that exists 
between the existing prostate cancer screening test (PSA alone) and the addition of a 
secondary test (biomarker clinical decision rule) to assess at what degree we could expect 
to improve PC screening by including the clinical decision rule into the PC screening 
process. 
 Mean and medium values of all significant biomarkers was determined for each 
PC stage subset to determine if there exists a gradient between advancing prostate cancer 
severity and increasing systemic disease severity (hypothesis 3). 
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Study Power   
A power calculation was performed prior to the start of the study. The exposure 
estimation was based on the mean number of JHVA male individual patients with 
abnormal laboratory values noted during 1998 through 2004. The denominator was the 
total number of male patients who underwent laboratory testing during the same time 
period. The calculation allowed us to conclude that the study has sufficient power (>0.80) 
to accurately detect an odds ratio of 2 with 95 percent confidence in the case population 
of 1,378 subjects is present. In addition, this calculation indicated that our study is 
designed and equipped to deal with larger than expected censured data loss, thus if a 
number of participants would have been lost, adequate study power will remain. An alpha 
value of 0.05 was the significant cutoff level throughout the analysis. 
7 - Variables 
Dependent 
 Hypothesis I & Hypothesis II - The outcome variable, prostate disease status; was 
defined as 1, for histological identification of PC and 0, for histological identification of 
BPH, PIN, and other non cancerous pathologies (i.e. prostatitis). 
 Hypothesis III – The outcome variable, prostate cancer severity, was defined as 3, 
(PC positive, organ confined, low grade); 2, (PC positive, palpable, moderate grade); 1, 
(PC positive, palpable, locally spread disease, moderate grade); 0, (PC positive, distant 
spread, high grade).   
Independent 
 The independent variables were treated as continuous, categorized, and binomial 
in the analysis.  There were 14 independent variables available for inclusion as predictor 
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variables in the logistical regression models. Four variables that were initially scheduled 
for analysis were dropped due to excessive participants with missing data (Pro-thrombin 
time/Partial pro-thrombin time (PT/aPTT), Folate, Lactate Dehydrogenase, and Total 
Protein). The 14 independent variables are outlined in Table 7 below. 
ID   
Age Continuous 
Age for subjects and was be calculated by 
subtracting the birth date from the date of 
disease determination.  
Histology Categorical 
Disease status will be coded as 1-‘prostate 
cancer’, 2-‘PIN’, 3-‘BPH’, 4-‘control group’. 
Stage Categorical  1-Stage A, 2-Stage B, 3-Stage C, 4-Stage D 
Gleason cat/continuous 1-10 
Ethnicity Categorical  
Obtained directly from the VA EMR. Coded 
as ‘White”, ‘Black’, ‘Hispanic’, and ‘Other’. 
ALB Continuous  
TBILI Continuous  
CREAT Continuous  
FLT Continuous  
HGB Continuous   
LDH Continuous   
MCV Continuous  
PLT Continuous  
PSA Continuous  
RBC Continuous  
UREAN Continuous  
HMTU Recoded 
Original data:  1 + H, LG, lg, MOD, NEG, 
neg., SM and TR. 
PRTU Recoded 
Original data: 1+ H, 100.0 H, 2+ H, 3+H, 30.0 
H, >300 H, NEG, neg., TR 
WBC Continuous  
PCYes Binary flag PC Yes=1, PC No = 0 
Black Binary flag  
Hispanic Binary flag  
Other/Unknown Binary flag  
HMTU2 
(Hematuria) Categorical 
Recoded- NEG, neg.=0 (negative), 1+H and 
TR=1 (trace), SM=2 (small), MOD=3 
(moderate), lg and LG=4 (large) 
PRTU2 Categorical 
Recode of PRTU.  NEG and neg.=0 (negative), 
TR=1 (trace), 1+H=2 (moderate), 2+ H=3, 3+ 
H and 100.0 H and >300 H and 30.0 H=4   
Table 7. Coding of the criterion and independent variables 
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8 - Summary 
 The overall aim of this study is to improve the efficiency of prostate cancer 
screening through the development of a clinical decision rule that is based on an elevated 
PSA and a predictive set of clinical biomarkers. This is a cross-sectional study evaluating 
men from the James Haley VA healthcare network from January 1, 1998 through April 
15, 2005. These men have undergone prostate biopsies as a result of an elevated PSA 
screening test (>4ng/dL). The target population is all men who utilize the VA healthcare 
system throughout the U.S. There are three hypotheses under evaluation:  
H1: Specific lab biomarkers among cases of prostate cancer will differ 
significantly from those patients without prostate cancer.   
H2:  In men with elevated PSA values, the addition of specific lab biomarkers 
will improve the effectiveness of predicting prostate cancer when compared to 
PSA alone. 
H3:  There exists a gradient between specified lab biomarkers and increasing 
levels of prostate cancer. 
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Chapter IV Results 
 
4.1 – Population Characteristics 
 
Demographics 
 Demographic data is outlined below in table 8. After study exclusions (see 
chapter III), there were 1,378 men available for analysis. The age range of the subjects 
was 40-95 (mean=68, SD=12). Most of the men had either prostatitis, BPH, or stage A 
PC. Prostate cancer (stage B, C, D) accounted for 20.6% of all diagnosis. The study 
population was largely Caucasian men (study total=70.75%, PC=69.4%, PIN=71.73%, 
BPH=74.82%, prostatitis=69.29%). Age at diagnosis (PC stage A group=68.37, PC stage 
B group=69.73, PC stage C group=67.73, stage D group 67.88, PIN group=67.75, BPH 
group=67.83, prostatitis group=68.17) was comparable across all diagnosis groups. 
 Prostatitis BPH PIN PC Stage A PC Stage B 
PC Stage 
C 
PC Stage 
D 
No. Subjects 342 282 138 332 220 48 16 
Ethnicity*        
Caucasian 237 (69%) 211(75%) 99 (72%) 238 (72%) 149 (68%) 31(65%) 10 (63%) 
African 
American 18 (5%) 19 (7%) 13 (9%) 34 (10%) 22 (10%) 7 (15%) 4 (25%) 
Hispanic 22 (6%) 14 (5%) 7 (5%) 15 (5%) 11 (5%) 1 (2%) 1 (6%) 
Other 65 (20%) 38 (14%) 19 (14%) 45 (13%) 38 (17%) 9 (18%) 1 (6%) 
Mean 
Age***  68.17 67.83 67.75 68.37 69.73 67.73 67.88 
SD Age 8.54 8.19 8.49 8.99 9.36 9.39 10.6 
Table 8. Demographics of Study Participants by Prostate biopsy results 
* P-value < 0.05 
** P-value <0.01 
*** Not statistically significant 
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Table 9 (below) outlines the mean value and standard deviation of all continuous 
laboratory biomarkers by the prostate biopsy results. The mean values of albumin, 
hemoglobin (HGB), RBC count, creatinine, and folate all decreased as the stage of PC 
increased. Conversely, the mean value of PSA increased as the stage of PC increased. For 
the laboratory biomarkers MCV, BUN, platlet count, WBC, LDH, and bilirubin, their 
mean values fluctuated without demonstrating any particular trend. 
A test for trend significance was additionally performed on table 8. As the 
prostate biopsy result increased from prostatitis to stage D PC, significant trends (p-value 
<.05) were noted for the mean value of HGB, creatinine, PSA, and BUN. Conversely, the 
lab biomarkers RBC, MCV, albumin, WBC, bilirubin, and platlet count did not 
demonstrate statistically significant trend changes. 
 Prostatitis 
N=342 
BPH 
N=282 
PIN 
N=138 
PC 
Stage A 
N=332  
PC 
Stage B 
N=220 
PC 
Stage C 
N=48 
PC 
Stage D 
N=16 
Albumin 
Mean 
SD    
 
 
4.00 
0.38 
         
   
  3.98 
  0.37 
   
 4.09 
  0.37 
  
 4.04 
 0.38 
  
 4.00 
 0.42 
  
  3.95 
  0.39  
 
3.90 
0.42 
HGB * 
Mean 
SD    
 
 
 14.27 
  1.54 
 
 14.24 
  1.76 
 
 14.30 
  1.68 
 
 14.17 
  1.66 
 
 13.70 
  1.87 
 
 12.59 
  2.20 
 
12.84 
14.08 
RBC  
Mean 
SD    
 
   
  4.67 
  0.46 
   
  4.65 
  0.52  
   
  4.76 
  0.52 
 
 4.69 
 0.50 
  
 4.63 
 0.57  
  
 4.58 
 0.44 
 
 4.50 
 0.67 
Creatinine* 
Mean  
SD 
 
   
  1.25 
  0.70 
   
  1.16 
  0.32 
   
  1.20 
  0.35 
  
 1.16 
 0.56  
   
  1.15 
  0.34 
  
 1.14 
 0.39  
 
1.13 
0.20 
 
PSA* 
Mean  
SD 
   
  8.06 
  6.74 
   
  7.99 
 11.20  
   
  7.67 
  4.58 
   
  9.70 
11.66 
 
14.12 
29.27 
 
21.85 
30.21 
 
44.03 
48.71 
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 Prostatitis 
N=342 
BPH 
N=282 
PIN 
N=138 
PC 
Stage A 
N=332  
PC 
Stage B 
N=220 
PC 
Stage C 
N=48 
PC 
Stage D 
N=16 
 
MCV  
Mean  
SD 
 
   
  90.78 
    4.65 
  
  91.13 
   5.35 
  
 90.09 
   5.79 
  
  91.17 
   5.05 
 
90.98 
  6.11 
  
 90.23 
   4.18 
 
92.24 
 4.99 
Bilirubin 
Mean  
SD 
 
    
   0.66 
   0.40 
  
 0.65 
 0.30 
 
 0.60 
 0.25 
 
  0.66 
  0.35 
 
  0.67 
  0.35 
 
  0.65 
  0.34 
 
 0.60 
 0.30 
BUN* 
Mean  
SD 
 
  
  17.98 
    6.93 
    
 
  17.60 
    7.90 
 
17.23 
  6.50 
 
 16.53 
   6.56 
 
 17.40 
   6.73 
 
 16.00 
   6.74 
 
15.97 
  4.54 
Platlet 
Mean  
SD 
 
  
  230.45 
    59.16 
 
  227.63 
    61.56 
 
240.81 
  84.31 
 
226.54 
  62.26 
 
232.50 
 69.25 
  
234.30 
   68.07 
 
235.44 
 50.76 
WBC  
Mean  
SD 
 
     
    7.24 
    2.11 
  
  7.11 
  2.17 
 
  7.42 
  3.24 
 
  7.19 
  2.42 
 
  7.13 
  2.08 
 
 10.41 
 17.78 
 
 7.37 
 1.84 
 
Folate 
Mean  
SD 
 
  
  
  12.93 
    5.44 
 
 
 12.56 
  5.78 
 
 
 12.31 
   5.29 
 
 
13.37 
  5.25 
 
 
 11.92 
   5.43 
 
 
 10.71 
   5.44 
 
 
10.03 
  4.99 
LDH  
Mean 
SD 
 
   
   426.91 
   375.09 
 
424.78 
144.84 
  
371.84 
 185.54 
 
404.60 
155.38 
 
406.41 
158.19 
 
392.11 
170.98 
 
393.33 
 73.76 
   
Table 9. Mean value and SD of Lab biomarkers by Prostate biopsy results 
* - Trend significance (P-value <.05) 
Testing the Hypothesis 
4.2 - Hypothesis 1: Among VA patients who have undergone prostate biopsies 
secondary to a PSA value of >4ng/dL, specified lab biomarkers* among cases of 
prostate cancer will differ significantly from those among VA patients without 
prostate cancer.     
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Crude Odds Ratios (with 95 % CI) for the association of each laboratory 
biomarker with prostate cancer is presented in three ways:  
• Method 1 - all stages of PC vs. non-cancerous prostate conditions   
• Method 2 - PC stages (B, C, D) vs. other (stage A PC, PIN, BPH, and 
prostatitis)   
• Method 3 - PC stages (B, C, D) vs. non-cancerous conditions (PIN, BPH, 
prostatitis). Stage A PC is excluded in this analysis method. This data is 
outlined in Table 10-12, respectively. 
Method 1 
There were 3 independent variables in this analysis that were statistically 
significantly related to the PC positive cases when compared to the control group (PC 
negative: PIN, BPH, and prostatitis) (Table 10). Initial crude analysis revealed 
hemoglobin, PSA, and serum BUN were significantly related; while age, hematuria, 
albumin, creatinine, MCV, platlet count, RBC count, bilirubin, and WBC were not 
statistically significant. 
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Covariates Included Odds Ratio OR 95% Confidence Interval 
HGB * 0.87 (0.82-0.93) 
AGE 1.01 (0.99-1.02) 
PSA* 1.04 (1.02-1.06) 
Hematuria 0.95 (0.86-1.06) 
Proteinuria 0.94 (0.83-1.07) 
Albumin 1.03 (0.78-1.36) 
Creatinine 0.76 (0.76-1.01) 
MCV 1.01 (0.99-1.03) 
PLT 1.00 (0.99-1.00) 
RBC 0.92 (0.75-1.13) 
Total Bilirubin 1.14 (0.84-1.55) 
BUN* 0.98 (0.96-0.99) 
WBC 1.01 (0.98-1.05) 
Table 10. Odds Ratio and 95% CI for Method 1: PC (all stages) vs. non-cancerous 
conditions, per laboratory unit 
* P-value significance at 0.05 
** P-value <0.01 
*** P-value <.001 
 
Method 2 
 
When the stage A PC subjects were placed in the comparison group (leaving stage 
B, C, and D PC subjects as the ‘cases’), there were 5 independent variables that 
demonstrated statistically significant relationships with the PC positive cases (when 
compared to the control group: stage A PC, PIN, BPH, and prostatitis). Initial bivariate 
analysis revealed hemoglobin, age, PSA, hematuria, and RBC count were the significant 
biomarkers, while albumin, creatinine, MCV, platlet count, bilirubin, BUN, and WBC 
were not.  
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Covariates Included Odds Ratio OR 95% Confidence Interval 
HGB * 0.79 (0.74-0.85) 
AGE* 1.02 (1.01-1.03) 
PSA* 1.04 (1.03-1.05) 
Hematuria* 1.23 (1.10-1.38) 
Proteinuria 1.16 (1.00-1.34) 
Albumin 0.77 (0.55-1.08) 
Creatinine 0.76 (0.52-1.12) 
MCV 1.00 (0.97-1.03) 
PLT 1.00 (0.99-1.00) 
RBC* 0.76 (0.59-0.98) 
Total Bilirubin 1.15 (0.80-1.66) 
BUN 0.99 (0.98-1.01) 
WBC 1.03 (0.99-1.06) 
Table 11. Odds Ratio and 95% CI for Method 2: PC (stage B, C, D) vs. other (PC 
stage A, PIN, BPH, prostatitis), per laboratory unit 
* P-value < 0.05 
** P-value <0.01 
*** P-value <0.001 
 
Method 3 
 
When the stage A PC subjects were dropped from the analysis process (leaving 
stage B, C, and D PC subjects as the ‘cases’, and PIN, BPH, and prostatitis subjects as the 
‘controls’), there were 3 independent variables that were significantly related to the PC 
positive cases. Initial bivariate analysis revealed hemoglobin, PSA, and hematuria were 
significantly related to PC, while age, proteinuria, albumin, creatinine, MCV, platlet 
count, bilirubin, BUN, and WBC were not (See table 12 below).  
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Covariates Included Odds Ratio OR 95% Confidence Interval 
HGB * 0.79 (0.73-0.85) 
AGE 1.02 (1.00-1.03) 
PSA* 1.06 (1.04-1.08) 
Hematuria* 1.15 (1.02-1.29) 
Proteinuria 1.09 (0.94-1.27) 
Albumin 0.83 (0.58-1.18) 
Creatinine 0.68 (0.46-1.02) 
MCV 1.00 (0.98-1.03) 
PLT 1.00 (0.99-1.00) 
RBC 0.77 (0.59-1.01) 
Total Bilirubin 1.19 (0.81-1.75) 
BUN 0.99 (0.97-1.01) 
WBC 1.02 (0.99-1.06) 
Table 12. Odds Ratio and 95% CI for Method 3: PC (stage B, C, D) vs. non-
cancerous conditions (PIN, BPH, prostatitis), per laboratory unit (stage A PC not in 
analysis) 
* P-value significance at 0.05 
 
Table 13 below summarizes the laboratory biomarkers which demonstrated a 
statistically significant relationship with PC. The lab biomarkers proteinuria, albumin, 
creatinine, platlet count, bilirubin, and WBC were not significantly related to PC in the 
crude analysis.  
Independent 
Variable 
     Method 1      Method 2         Method 3 
Hemoglobin 
(HGB) 
            ***                  
 
              ***                *** 
RBC count                *  
BUN             *   
Hematuria                *               * 
PSA             ***               ***               *** 
Age                *                  * 
Table 13. Summary table of independent variables that demonstrate statistically 
significant relations with PC (by analysis methods 1-3) 
* P-value <0.05 
** P-value <0.01 
***P-value <0.001  
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4.3 - Hypothesis 2: Among VA patients who have undergone prostate biopsies 
secondary to a PSA value of >4ng/dl, the addition of specified lab biomarkers* will 
improve the effectiveness of predicting the presence of prostate cancer when 
compared to PSA alone. 
Comparison 
Groups 
Method 1 Method 2 Method 3 
PC Cases/Total 
biopsies 
616/1,378 284/1,378 284/1,046 
Positive Predictive 
Value 
44.7% 20.6% 27.2% 
Table 14. Positive Predictive Value of PSA > 4ng/dL 
Method 1: PC (all stages) vs. non-cancerous conditions (PIN, BPH, prostatitis) 
Method 2:  PC (stage B, C, D) vs. other (stage A PC, PIN, BPH, prostatitis) 
Method 3: PC stage (B, C, D) vs. non-cancerous conditions (PIN, BPH, prostatitis) 
 
Table 14 outlines the PPV of PSA (4ng/dL) alone for detecting prostate cancer. 
This PPV was evaluated 3 different ways: 
• Method 1 - all stages of PC vs. non-cancerous prostate conditions 
• Method 2 - PC stages (B, C, D) vs. other (stage A PC, PIN, BPH, and prostatitis) 
• Method 3 (stage A PC excluded) - PC stages (B, C, D) vs. non-cancerous 
conditions (PIN, BPH, prostatitis), respectively.  
The positive predictive value was decreased significantly when stage A PC was 
not considered as a case. In particular, the PPV decreased by 24.1% when the stage A PC 
group was considered as in the comparison group (non-diseased). 
To begin the regression process, a full model was assimilated, including all 
laboratory biomarkers, age, and ethnicity. Multiple models were then run, excluding each 
covariate, one by one, to assess the change of the -2 Log Likelihood value and the C-
statistic. The evaluation process continued until the most parsimonious model with the 
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lowest -2 Log Likelihood value and highest C-statistic was determined for each of the 3 
analysis methods (tables 15-17 below).   
Interaction terms were evaluated for each of the 3 analysis methods. While the 
overall change to the of the -2 Log Likelihood value and the C-statistic were minimal and 
not statistically significant, the interaction between age and HGB and age and PSA were 
significant (p-value <.05).  For a 50 year old man, the OR for HGB and PSA would be 
(1.02, 95%CI 1.01-1.04, respectively. For a 70 year old man, the comparable OR would 
be (1.03, 95%CI 1.01-1.04), respectively. This interaction was noted to be of quantitative 
rather than qualitative significance.   
 
Parameter 
ML 
Est. SE OR 95% CI C stat -2 LL 
Intercept -7.9494 1.88      xx     xx 0.68 1777.339
HGB** -0.3519 0.06 0.70 (0.63-0.79)     
RBC** 0.9227 0.21 2.52 (1.67-3.78)     
Hematuria** -0.2874 0.15 0.75 (0.56-1.01)     
Creatinine** -0.4393 0.17 0.65 (0.47-0.89)     
Black** 0.6336 0.21 1.89 (1.25-2.90)     
PSA** 0.0408 0.08 1.04 (1.03-1.06)     
AGE** 0.0196 0.01 1.02 (1.01-1.03)     
MCV** 0.0663 0.02 1.07 (1.04-1.10)     
Albumin*** 0.2871 0.16 1.33 (0.98-1.82)     
Table 15. Best fit Logistical Regression for Method 1: Risk of PC with Lab 
biomarkers and 95% CI, per laboratory unit 
Method 1: PC (all stages) vs. non-cancerous conditions (PIN, BPH, prostatitis) 
** p-value <.05, *** Not significant 
 
 
 Table 16. Best fit logistical regression model for Method 2: Risk and 95% CI for PC 
with lab biomarkers, per laboratory unit 
Parameter ML Est. SE OR 95% CI C Stat -2 LL 
Intercept -5.1041 xx xx xx 0.713 1276.366 
HGB** -0.3784 0.05 0.69 (0.62, 0.76)   
RBC** 0.7641 0.21 2.15 (1.43, 3.23)   
Creatinine** -0.6069 0.23 0.55 (0.35, 0.85)   
PSA ** 0.0325 0.01 1.03 (1.02, 1.05)   
Age** 0.0183 0.01 1.02 (1.01, 1.04)   
MCV** 0.0488 0.02 1.05 (1.02, 1.08)   
Black*** 0.3612 0.24 1.44 (0.90, 2.31)   
* P-value <0.05, ** P-value <0.001, *** Not significant 
 
 
Parameter ML Est. SE OR 95% CI C stat -2 LL 
Intercept** -6.8083 2.2821 xx xx 0.742 1077.58 
HGB*** -0.4720 0.0658 0.62 (0.55, 0.71)   
RBC** 1.1051 0.2516 3.02 (1.84, 4.94)   
Creatinine** -0.8150 0.2543 0.44 (0.27, 0.73)   
Black* 0.6092 0.2664 1.84 (1.09, 3.10)   
PSA*** 0.0540 0.0090 1.06 (1.04, 1.08)   
AGE* 0.0238 0.0010 1.02 (1.01, 1.04)   
MCV** 0.0658 0.0181 1.07 (1.03, 1.11)   
Table 17. Best fit logistical regression model for Model 3: Risk and 95% CI for PC 
with Lab biomarkers, per laboratory unit 
 Method 3: PC stage (B, C, D) vs. non-cancerous conditions (PIN, BPH, prostatitis) 
PC stage A excluded from analysis 
* P-value <.05 
** P-value <.01 
*** P-value <.001 
 
The ROC curves below demonstrate the validity that was yielded for analysis 
method 1-3, respectively. These ROC curves demonstrates the difference that exists 
between the existing prostate cancer screening test (PSA alone) and the secondary 
screening test to assess at what degree can we expect to improve PC screening by 
including this secondary rule into the PC screening process (see figures 2-7 below).  
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Confidence intervals between PSA alone and the clinical decision rule models (PSA + lab 
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biomarkers) did not overlap and were statistically significantly different. The ROC AUC: 
Method 1 PSA alone 0.59, (95% CI 0.55, 0.61) to CDR (PSA+ significant lab 
biomarkers) 0.68 (95% CI 0.65, 0.71); Method 2 PSA alone 0.63, (95% CI 0.58, 0.66) to 
CDR (PSA+ significant lab biomarkers) 0.72 (95% CI 0.68, 0.75); Method 3 PSA alone 
0.64 (95% CI 0.59, 0.68) to 0.74 CDR (PSA+ significant lab biomarkers) (95% CI 0.71, 
0.78). 
 ROC Curves:  Figures 2-7. 
 
 
        Figure 2. Diagnostic statistics = ROC curve of PSA Alone - Method 1 
 
  
 
             Figure 3. Diagnostic statistics = ROC curve of PSA + lab biomarkers - Method 1 
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               Figure 4.Diagnostic statistics = ROC curve of PSA Alone - Method 2 
 
                              
             
 
 
               Figure 5. Diagnostic statistics = ROC curve of PSA + lab biomarkers - Method 2 
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            Figure 6. Diagnostic statistics = ROC curve of PSA Alone - Method 3 
 
             
 
            Figure 7. Diagnostic statistics = ROC curve of PSA + lab biomarkers - Method 2 
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 For determining the ideal cut-points for recommending prostate biopsy, 4 
different cut-points where chosen, each providing either increased sensitivity or 
specificity. The cut-points are presented in four ways:  
• Cut-point 1 – The maximum likelihood ratio. This was determined by dividing 
the sensitivity by 1- the specificity (SEN/1-SPC), thus maximizing the quotient.  
• Cut point 2 – The probability that yielded a sensitivity of approximately 90% 
with the highest corresponding specificity.  
• Cut point 3 - The probability that yielded a sensitivity of approximately 80% with 
the highest corresponding specificity.  
• Cut point 4 - The probability that yielded a specificity of approximately 80% with 
the highest corresponding sensitivity. This data is outlined in Table 18- 19, 
respectively.  
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 Method 1 Method 2 Method 3 
Cut-point 1 (MLE) Probability .45 Probability .41 Probability .42 
     Sensitivity 52.1 % 18.3 % 33.5 % 
     Specificity 74.0 % 96.2 % 93.4 % 
     PPV 61.8 % 55.3 % 65.5 % 
     NPV 65.7% 81.9 % 79.0 % 
Cut-point 2 (Sen. 
90%) 
Probability .33 Probability .13 Probability .17 
     Sensitivity 90.9 % 89.8 % 90.1 % 
     Specificity 17.6 % 28.0 % 31.1 % 
     PPV 47.1 % 20.6 % 32.8 % 
     NPV 70.5 % 91.3 % 89.4 % 
Cut-point 3 (Sen. 
80%) 
Probability .37 Probability .15 Probability .20 
     Sensitivity 80.5 % 78.2 % 78.9 % 
     Specificity 37.1 % 45.0 % 49.9 % 
     PPV 50.9 % 28.7 % 37.0 % 
     NPV 70.2 % 88.8 % 86.4 % 
Cut-point 4 (Spc. 
80%) 
Probability .48 Probability .23 Probability .29 
     Sensitivity 39.9 % 45.8 % 52.1 % 
     Specificity 81.4 % 79.5 % 81.8 % 
     PPV 63.4 % 36.7 % 51.6 % 
     NPV 62.6 % 85.0 % 82.1 % 
Table 18. Sensitivity, Specificity, PPV, and NPV for probability cut-off points  
 
 
 Method 1 Method 2 Method 3 
Crude PPV 44.7 % 20.6 % 27.2 % 
Cut-point 1 61.8 % 55.3 % 65.5 % 
Cut-point 2 47.1 % 20.6% 32.8 % 
Cut-point 3 50.9 % 28.7% 37.0 % 
Cut-point 4 63.4 % 36.7% 51.6 % 
Table 19. Comparison of PPV between PSA (>4ng/dL) and cut-points 1-4 by 
analysis method 
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4.4 - Hypothesis 3: Among VA cases of histologically confirmed prostate cancer, 
there exists a gradient between specified lab biomarkers* and increasing stage of 
prostate cancer. 
To evaluate hypothesis III, the mean values of each specified lab parameter (with 
accompanying 95 % CI) was determined for each PC stage. If there exists a gradient 
between the lab biomarkers and increasing stage of PC severity, one would expect to see 
a change in the mean value of the biomarker (away from the normal expected level) as 
the PC stage increases. This set of circumstances is seen in mean change of the lab 
biomarkers HGB, RBC, Albumin, and PSA (Table 20, below). 
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 PC Stage A 
N=332  
PC Stage B 
N=220 
PC Stage C 
N=48 
PC Stage D 
N=16 
Albumin 
Mean 
SD 
95%CI    
  
 4.04 
 0.38 
(4.00, 4.08) 
  
 4.00 
 0.42 
(3.96, 4.05) 
  
  3.95 
  0.39  
(3.84, 4.06) 
 
   3.90 
   0.42 
(3.69, 4.11) 
HGB  
Mean 
SD 
95%CI    
 
  14.17 
    1.66 
(14.00, 14.35)
 
 13.70 
  1.87 
(13.45, 13.95) 
 
 12.59 
  2.20 
(11.97, 13.21) 
 
  12.84 
  14.08 
(5.94, 19.74) 
RBC  
Mean 
SD 
95%CI   
 
   4.69 
   0.50 
(4.64, 4.74) 
  
   4.63 
   0.57 
(4.55, 4.71) 
  
   4.58 
   0.44 
(4.46, 4.70) 
 
 4.50 
 0.67 
(4.17, 4.83) 
Creatinine 
Mean  
SD 
95%CI 
  
 1.16 
 0.56 
(1.10, 1.22) 
   
   1.15 
   0.34 
(1.11, 1.20) 
  
 1.14 
 0.39 
(1.03, 1.25)  
 
   1.13 
   0.20 
(1.03, 1.23) 
PSA  
Mean  
SD 
95%CI 
   
     
    9.70 
  11.66 
(8.45, 10.95) 
 
   
   14.12 
   29.27 
(10.25, 17.99) 
 
    
    21.85 
    30.21 
(13.31, 30.39) 
 
   
   44.03 
   48.71 
(20.16, 67.90) 
MCV  
Mean  
SD 
95%CI 
  
  91.17 
   5.05 
(90.63, 91.71)
 
   90.98 
     6.11 
(90.17, 91.79) 
  
 90.23 
   4.18 
(89.05, 91.41) 
 
   92.24 
     4.99 
(89.79, 94.69) 
Bilirubin 
Mean  
SD 
95%CI 
 
    0.66 
    0.35 
 (0.28, 1.04) 
 
    0.67 
    0.35 
(0.62, 0.72) 
 
    0.65 
    0.34 
 (0.60, 0.70) 
 
    0.60 
    0.30 
(0.45, 0.75) 
BUN  
Mean  
SD 
95%CI 
 
    16.53 
      6.56 
(15.82, 17.24)
 
    17.40 
      6.73 
(16.51, 18.29) 
 
 16.00 
   6.74 
(17.91, 14.09) 
 
    15.97 
      4.54 
(13.74, 18.20) 
Platlet 
Mean  
SD 
95%CI 
 
226.54 
  62.26 
(219.8, 233.2)
 
   232.50 
     69.25 
(223.4, 241.7) 
  
 234.30 
   68.07 
(215.1, 253.6) 
 
235.44 
 50.76 
(210.6, 260.3) 
WBC  
Mean  
SD 
95%CI 
 
  7.19 
  2.42 
(6.93, 7.45) 
 
   7.13 
   2.08 
(6.86, 7.40) 
 
   10.41 
     1.78 
(9.91, 10.91) 
 
    7.37 
    1.84 
(6.47, 8.27) 
Table 20. Mean value, SD, and 95% CI of Lab biomarkers by PC stage 
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A trend analysis was performed to determine whether or not the change seen with 
lab biomarkers HGB, RBC, Albumin, and PSA was statistically significant. This trend 
analysis was performed through linear regression modeling. These linear models were 
analyzed by first coding each continuous laboratory biomarkers as the criterion variable, 
with the PC stage coded as the predictor variable. The model results suggest that PC stage 
is a significant statistical predictor for gradient changes in the laboratory biomarkers 
HGB, RBC count, albumin, and PSA (table 21, below). The four subsequent graphs 
further demonstrate the change in mean value by PC stage for each significant lab 
biomarker. 
Criterion 
Parameters 
Parameter 
Estimate SE T value 
R 
square 
Adjusted 
R square F value  
Biomarker 
change 
HGB* -0.58752 0.099 -5.96 0.0547 0.0532 35.54 0.555 
RBC* -0.06291 0.028 -2.22 0.0079 0.063 4.91 0.939 
MCV- NS -0.11639 0.292 -0.4 0.0003 -0.00014 0.16         XX 
Creat. - NS  -0.009 0.026 -0.37 0.0002 -0.0014 0.14         XX 
Albumin* -0.0483 0.021 -2.26 0.0083 0.0067 5.12 0.953 
PSA* 7.458 1.227 6.08 0.0568 0.0552 36.95 1733.6 
Table 21. Results of Linear Regression modeling of lab biomarker by PC stage 
* P-value <.05 
 ** P-value <.001 
*** P-value <.001  
NS-Not statistically significant 
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Figure 8. Mean Hemoglobin value by PC stage 
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  Figure 9. Mean Albumin value by PC stage 
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  Figure 10. Mean RBC count by PC stage 
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  Figure 11. Mean PSA value by PC stage 
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Chapter V: Discussion 
5.1 - Introduction (Chapter I-III Review) 
A search of peer reviewed published literature failed to identify any studies that 
evaluate whether (or not) combinations of laboratory biomarkers, used in concurrence 
with an elevated PSA, increase the detection of screened identified PC. However, 
previous research has demonstrated that specific systems are altered as PC increases in 
stage and severity.29, 30, 32, 92 In particular, anemia (either iron defiency or anemia of 
chronic disease) is a frequent complication of PC, and hematuria is a common finding in 
patients with prostate tumors that have spread outside of the prostate capsule, but have 
not yet spread to distant body regions.33 In multiple published studies, decreased 
hemoglobin has been reported as an independent risk factor for decreased survival 
outcomes in patients with hormone refractory prostate cancer.91 Moreover, previous 
research has demonstrated that PSA has limitations (e.g. poor validity and reliability) and 
there is room for improvement. 1, 8, 11  
A primary goal of PC screening is to detect the cancers before they are too 
advanced for treatment, and to bypass the tumors that are not destined to become 
deleterious in the patient’s lifetime.106 With that stated, delineation between the different 
types of PC is difficult, but of paramount importance.  Earlier PSA research by Catalona, 
the U.S. Preventive Task Force and more recent work by Thompson, Carter, the PLCO 
(and others), has been critical in improving our ability to identify PC at earlier disease 
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stages.11, 25, 106 However, there is continued debate over the utility of PSA as a screening 
tool for prostate cancer.8 Is it the best currently available tool for the detection of pre-
clinical PC? This debate is likely to continue until the results of the PLCO trial are 
released (tentatively scheduled for 2014).  
 How can PC screening be improved? Despite a wealth of published literature that 
has evaluated PSA and argued against its use as a PC screening tool, PSA remains the 
mainstay for clinicians for PC screening. Thus, the focus must be on augmenting PSA, 
not replacing it altogether. Prior attempts at improving PC screening have focused on 
replacing PSA with a new test. Tools such as PSA velocity, PSA density, Free/Total PSA 
ratio have all shown promise in studies for improving PC screening results, but difficult 
implementation and a lack of universal acceptance among clinicians have hindered their 
incorporation into daily clinical practice.7, 23, 26, 27, 40, 41, 41, 86  
Have researchers and clinicians made the most of all available information when 
evaluating a patient for prostate cancer? Routinely ordered lab panels (complete blood 
count, basic metabolic panels, and urinalyses) all contain biomarkers that change in value 
when diseases associated with prostate cancer are present. Yet these biomarkers have not 
been utilized when evaluating a patient for PC. Many previous studies have accurately 
described PSA elevations as ‘specific to a condition of the prostate’.8, 18 However, these 
PSA elevations are not specific to prostate cancer. In what may hold the key to improving 
the overall yield of PC screening; evaluating changes in certain laboratory biomarkers 
values (in the presence of an elevated PSA) that are associated with diseases that are a 
product (either directly or indirectly) of PC spread may provide a wealth of important 
information that can improve the validity and reliability of PC screening.  
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5.2 – Review of Main Findings (Chapter IV) 
 A primary goal of PC screening is to detect the cancers before they are too 
advanced for treatment, and to overlook the tumors that are not destined to become 
deleterious in the patient’s lifetime.106 With that stated, 2 questions arose during the 
course of this study. Given that stage A (non-palpable, organ confined) PC often is 
undetectable and offers little biological evidence of its presence, does its inclusion in this 
analysis mitigate the difference between the clinically important PC and non-cancerous 
prostate disease? Are the laboratory biomarkers under evaluation related more to more 
advanced (or aggressive) PC stages?  To answer these questions, the statistical analysis 
procedures were performed utilizing 3 different methods. For method 1, stage A PC was 
included as a ‘case’, for method 2, stage A PC was included as a ‘control’, and in method 
3, stage A PC was excluded from the analysis altogether. The intent in evaluating the data 
by multiple methods is to develop a clinical decision rule that can provide clinicians and 
patients information on the probability of the presence/absence of PC, and if it is PC, the 
likely stage of the cancer, prior to prostate biopsy.     
 This study hypothesized that specific lab biomarkers among cases of PC would 
differ significantly from those patients without PC.  The countering null hypothesis states 
the specific laboratory biomarkers do not differ between the PC patients and non-
cancerous patients. This hypothesis was evaluated by both bivariate (e.g. one outcome 
variable, one independent variable) and multivariate analysis techniques. Initially, 
analysis method 1 demonstrated that HGB, PSA, and serum BUN were significant 
variables (see chapter IV table 10). The relationships were then re-evaluated with 
multiple logistic regression, and a more precise picture began to develop. Additional 
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significant predictor variables emerged, and serum BUN was not significant in the 
multivariate model. Throughout the method 1 modeling process, HGB (OR=1.42 95%CI 
1.27-1.59), RBC count (OR=2.52 95%CI 1.67-3.78), PSA (OR=1.04 95%CI 1.03-1.05), 
serum creatinine (OR=1.55 95%CI 1.12-2.15), and the ethnicity variable ‘Black’ 
(OR=1.88 95%CI 1.25-2.85) were significantly related to the PC group. Under conditions 
where all other predictor variables are held constant; both HGB (point estimate -.3519 p-
value <.0001) and creatinine (point estimate -.4393 p-value .008) demonstrated increased 
PC risk with a 1 unit negative change in their value; while RBC count (point estimate 
.9227 p-value <.0001), age (point estimate .0196 p-value <.005), PSA value (point 
estimate .0408 p-value <.005), MCV level (point estimate .066 p-value <.0001), and 
serum albumin (point estimate .2871 p-value .071) demonstrated increased PC risk of 1 
unit positive increase in their respected values. 
 Analysis method 2 (stage A included in the comparison group) crude analysis 
demonstrated HGB, PSA, RBC count, hematuria, and age were significant variables (see 
chapter IV, table 11). Multiple regression modeling demonstrated HGB (OR 0.68 95%CI 
0.62, 0.76), RBC (OR 2.15 95% CI 1.43, 3.23), serum creatinine (OR 0.545 95%CI 0.35, 
0.85), PSA (OR 1.033 95%CI 1.02, 1.05), MCV (OR 1.05 95%CI 1.02, 1.08), and age 
(OR 1.018 95%CI 1.01, 1.04) were all significant after all other predictor variables were 
held constant.  
 Analysis method 3 (stage A excluded from the analysis); the crude analysis 
revealed HGB, PSA, and hematuria were significant variables (see chapter IV, table 12). 
Multiple regression modeling demonstrated HGB (OR 0.62 95%CI 0.55, 0.71), RBC (OR 
3.02 95% CI 1.84, 4.94), serum creatinine (OR 0.44 95%CI 0.27, 0.73), PSA (OR 1.06 
 98 
95%CI 1.04, 1.08), MCV (OR 1.07 95%CI 1.03, 1.11), and age (OR 1.02 95%CI 1.01, 
1.04) were all significant after all other predictor variables were held constant.  
             The second hypothesis stated ‘the addition of specific lab biomarkers will 
improve the effectiveness of predicting prostate cancer when compared to PSA alone’. 
The countering null hypothesis is, ‘there is no difference between the two models’. To 
address this question, ROC curves were employed. ROC curves measure the probability 
of correct diagnostic classification, i.e. the test accuracy.114 I compared the ROC curve of 
the best fit model for analysis methods 1-3 to the ROC curves of PSA (4ng/dL) to 
determine if the area under the curve (AUC) between the models and the PSA model are 
significantly different. In addition, the 95 % CI was determined for all models. The AUC 
increased from: Method 1 PSA alone 0.59, (95% CI 0.55, 0.61) to CDR best fit model 
0.68, (95%CI 0.65, 0.71); Method2 PSA alone 0.63, (95% CI 0.58, 0.66), to CDR best fit 
model 0.68, (95% CI 0.68, 0.75); Method 3 PSA alone 0.64, (95%CI 0.59, 0.68), to CDR 
best fit model 0.74 (95% CI 0.71, 0.78). This indicates that the difference between the 
models is significant, thus the null hypothesis of no difference is rejected. In addition to 
the ROC curve, the validity (sensitivity/specificity) and predictive values (positive 
predictive value/negative predictive value) were determined for the best fit model. For 
the PSA only model, one can only determine the positive predictive value, given patients 
with a PSA less than 4ng/dL are not routinely forwarded for prostate biopsy. The PPV of 
PSA (>= 4ng/dL) decreased from 44.7% (method 1) to 20.6% (method 2). This indicates 
PSA is less effective as a tool for identifying the more clinically relevant PC (stage B, C, 
and D). Conversely, looking at method 2, cut-point 1 (see chapter IV, table 18) the 
sensitivity of this model was 18.3%, specificity was 96.2%, NPV 81.9%, and a PPV at 
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55.3% These values are increased over the validity and predictive values that have been 
published in previous studies that attempted to clarify the ambiguity surrounding PSA 
sensitivity and specificity. This indicates that this model could improve our ability to 
detect clinically important PC. Moreover, depending on the cut-off point, the study offers 
hope that the number of unnecessary biopsies performed within the JH VA could be 
reduced.   
The third hypothesis under evaluation was whether there exists a gradient of 
change between the significant lab biomarkers and increasing levels of PC. Four of the 
laboratory biomarkers did demonstrate a gradient with increasing stage of PC 
(hemoglobin, RBC, PSA, and albumin). For the stage IV PC, the small number of cases 
led to unstable point estimates, large confidence intervals, and it is suspected that if the 
numbers in this group increased, a similar gradient trend would materialize.  
To evaluate the statistical significance of the gradient, linear regression analysis 
was performed. Each continuous laboratory biomarker was modeled as the outcome 
variable, with PC stage (A-D) modeled as the predictor variable. In addition to PSA, the 
variables hemoglobin, RBC count, and albumin demonstrated a significant difference 
between each PC stage (see chapter IV, table 21). These results indicate that the degree of 
change between the reference ‘normal’ value and the observed lab value could provide 
valuable insight for detecting PC, and improve our ability to differentiate between 
indolent PC and clinically relevant PC. 
 These results suggest that evaluation of additional laboratory biomarkers (in 
conjunction with an elevated PSA) might improve our ability to detect prostate cancer; 
while also decreasing the number of non-diagnostic prostate biopsies. Moreover, the 
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results seem to indicate that the evaluated biomarkers may be more helpful in detecting 
clinically relevant cancer. After evaluating stage A PC in the comparison group, the PPV 
of PSA alone was 20.6% (284/1378). The CDR ‘parsimonious’ model (Method 2, cut-
point 1), yielded a positive predictive value of 55.3% (52/94). With a specificity of 96.2% 
and a sensitivity of 18.3%, this model can reduce the number of unnecessary biopsies 
from 1,092 to 92. With a specificity of 96.2%, this clinical decision rule model will 
correctly identify more than 9 out of every 10 men who have do not have PC. In 1998, 
the JH VA performed 1,610 biopsies. If one were to apply this clinical decision rule 
(comparing PC stage B, C, D vs. stage A PC, PIN, BPH, and prostatitis) to the 1,378 
subjects within this study, 52 of the 92 total biopsies (PPV= 55.3%) would have been 
positive for PC (stage B,C,D) (PSA alone=PPV 44.7%). In addition, if this clinical 
decision rule would have been employed, approximately 1,052 negative biopsies would 
not have been performed. This would have resulted in decreased cost for the VA hospital 
network, reduced anxiety and stress for patient, and a reduced risk of biopsy morbidity 
(given the biopsies would have never been performed). 
5.3 - Consistency with Literature 
 There were many areas of this study that were consistent with prior published, 
peer reviewed studies. In particular, the proportion of PC that was localized to the 
prostate is consistent with the stage shift phenomenon (increased amounts of pre-clinical 
disease detected when compared to ways other than screening) seen with PC screening. 
Stage A comprised 53.9 % of all the PC cases; Stage B 35.7 %; Stage C 7.8 %; and Stage 
D 2.59 % (appendix: table 22). A stage shift towards less invasive disease at presentation 
has been attributed to PC screening and this scenario was seen in this study.  
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 Secondly, all laboratory biomarkers demonstrated ‘movement’ in the direction 
away from the ‘normal’ value that is consistent with previous literature and is 
biologically plausible.101 For instance, PSA has been known to be elevated in both 
cancerous and non-cancerous prostate conditions.1 This was seen in this study, as the 
range of the mean PSA value increased from 7.67 (prostatitis) to 44.03 (stage D PC). 
Multiple published studies have reported that a low hemoglobin value is an independent 
risk factor for deleterious survival outcomes in patients with hormone refractory prostate 
cancer.91 In addition; the correlation between PC and hematologic disorders has been long 
recognized for its clinical significance, with anemia a frequent clinical manifestation of 
advancing PC.101 In this study, the laboratory parameters HGB, RBC count, and MCV 
(all indicators of hematologic state) demonstrated values below their normal reference 
range (in patients with clinically relevant PC).  When comparing the subjects with 
histologically confirmed prostatitis to patients with histologically confirmed stage C PC, 
the difference becomes evident. HGB decreased from 14.27 to 12.59, RBC count 
decreased from 4.67 to 4.58, and MCV decreased 90.78 to 90.23 (HGB and RBC count 
were statistically significant trends), respectively.  In addition, it has been previously 
described that decreased creatinine has been linked to decreased muscle mass and severe 
liver disease (seen in patients with advancing PC).35 In this study, creatinine 
demonstrated a decreasing trend as PC stage increased (1.16 to 1.13), although it was not 
statistically significant.   
 African-American ethnicity increased the risk of PC in men undergoing biopsy. 
There was an 83% increase in the risk of PC for African-American men when compared 
to Caucasian men. This is consistent with previous literature which describes PC 
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incidence and mortality rates as disproportionately higher in African-American males 
than white males in the United States (up to two times higher).44  
 Advancing age is one of three non-modifiable risk factors for PC.10 The incidence 
and prevalence of prostate cancer increases as men become older.10 In this study, the 
mean age of subjects in this study was not significantly different. However, a one year 
increase in age did increase the odds of PC development by 2% (which was statistically 
significant).   
5.4 - Internal Validity 
 
 There were specific study limitations that were identified during the performance 
of this study. Concerns with selection bias, incomplete data, misclassification of the 
outcome, and uncontrolled confounding were acknowledged and are outlined below. In 
addition, the perceived study strengths are outlined as well. 
5.4.1- Selection Bias  
 One concern of this study was the potential for selection bias on obtaining 
prostate biopsies. It was believed that clinicians within the VA network follow an 
algorithm for sending patients for prostate biopsy. If a patient had an elevated PSA test, 
they would be referred onward for prostate biopsy. However, in the JH VA, do all men 
with an elevated PSA actually undergo prostate biopsy? As a check for internal validity 
(and to ensure selection bias is not present), further evaluation of this question was 
warranted. A search through the VISTA system was initiated to capture all PSA lab tests 
performed for the years 1998, 2000, and 2002. They were then sub-categorized for PSA 
values greater than 4ng/dL.  This list was then crossed referenced against the list of 
patients that had a recorded prostate biopsy during the study period (1998-2004) 
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(SNOMED codes: 77220, 77103, 77102, 77101, 77110, 77105, 77350, 77230, 77210, 
77300, 77200, 77240, 77104, 77100, 77000, 77900, and 77250). During this period, there 
were 442,000 PSA tests performed at the JH VA, of which 3,425 patients had a value of 
greater than 4ng/dL. Of the 3,425 patients with elevated PSA values, 1,610 had 
undergone a prostate biopsy, and 1,810 had not (52.9%). Further investigation was 
needed to explain why over half of the patients with elevated PSA values did not undergo 
a biopsy. After much investigation and discussion with both JH VA Urology and 
Pathology physicians, it was determined that approximately 75% of the 1,810 elevated 
PSA values were of patients status post PC treatment (prostatectomy, radiation, 
cryotherapy, etc.), and had actually undergone a prostate biopsy before the timeline of 
this study, thus their biopsy results were not captured during the original VISTA search.  
It is important to note that PSA is used more frequently as a tool for post PC treatment 
follow-up than for screening.106 It is considered the standard of care for all post-treatment 
PC patients to have an annual PSA draw to monitor for refractory prostate cancer. In 
addition, it was estimated that 12.5% of all patients that are found to have elevated PSA 
values through the VA medical network choose to have their care outside the VA 
network. Therefore, their specific treatment information is not available for analysis. It is 
estimated that 88-90 % of all participants in this study found to have an elevated PSA 
through screening were referred for evaluation via prostate biopsy.  
5.4.2 - Incomplete data 
Certain laboratory biomarkers had incomplete data which lead to the exclusion of 
these variables for analysis and interpretation. Although clinicians often obtain a 
complete blood count (CBC), basic metabolic panel (BMP), and urinalysis (UA) at the 
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time of the screening PSA test, certain laboratory assays (e.g. PT/aPTT, and Folate) are 
not routinely included in these panels, thus they are not requested. Both PT and aPTT are 
used to evaluate the coagulation system, with increasing levels of both being an 
independent predictor of DIC (a systemic condition seen occasionally with metastatic 
PC).75 High plasma levels of Folate has been previously reported as both protective and 
as a risk factor for PC development.125 Given the plausible links to PC, they were of 
particular interest for this study. There are no current guidelines that recommended 
additional laboratory tests for PC screening; therefore clinicians do not make the request 
for such additional tests. This lack of data limits the strength of the analysis and 
interpretation of the results.   
5.4.3 - Misclassification of outcome 
 Although each prostate biopsy was evaluated by two or more trained pathologists, 
the possibility that misclassification of disease status (i.e. patients who have PC were 
classified as ‘no PC’) does exist. Given that the outcome variable (PC yes or no) is 
determined by the results of a prostate biopsy, and that the biopsies themselves are a 
sampling of the entire prostate, there is a chance that the biopsy did not contain cancerous 
cells, yet the prostate itself does. If this scenario occurred, the patient would be 
categorized as ‘no PC’, when in fact they do have PC. When there are two outcome 
categories being compared (in this case, “PC yes/no”), this misclassification can bias the 
association either away or towards the null hypothesis. However, it is unlikely that an 
individual would be categorized as having PC if the carcinoma was not present on 
histological sample. Therefore if misclassification is present, it is more likely that a 
patient with PC is misclassified as not having prostate cancer, than a patient without PC 
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being classified as having the disease. 
5.4.4 - Uncontrolled confounding 
 Certain variables that were initially recommended for collection were not 
available for analysis; therefore this study’s results may be a result of confounding. 
Specifically, information on family history of PC was found to be lacking in both the 
urological and general clinic patient encounter notes; and family history on any medical 
condition was available in less than 50 % of the study participants. In addition, social 
history (tobacco and alcohol use) and socio-economic status (which have been previously 
described as potential modifiable risk factors for PC) were initially scheduled for 
evaluation. Unfortunately, this information was also missing on a large percentage of the 
study participants (75%) and therefore unavailable for analysis. 
5.4.5 – Study Strengths 
 The strengths of this study include the data quality, study population size, biologic 
plausibility, and the type of analysis performed.  
The quality of the data was increased in that the diagnosis of prostate disease 
status was discerned from histologic evaluation of biological materials obtained from 
invasive prostate biopsy by at least two highly trained clinical pathologists. In addition, 
the use of laboratory data eliminates the chance of recall and interviewer bias entering the 
study.  The ethnicity of each study participant was obtained from two different data sets 
to increase reliability of the variable.  
The study population was 1,378 subjects, of which 616 were prostate cancer 
patients. This high proportion of cases increases overall study power and statistical 
efficiency (more likely to have stable parameter estimates and identify effect 
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modification between independent variables). This increased study power allowed for 
stratification on key parameters, such as PC stage and ethnicity. 
 The results are biologically plausible. The results of this study are consistent with 
what existing knowledge. It is accepted within the medical community that there is a 
relationship between PC and systemic diseases that occur in presence of both local and 
metastatic spread of PC.101 Moreover, it has been demonstrated that the specified 
laboratory biomarkers evaluated in this study are highly correlated with the systemic 
diseases related to PC spread.21   
 The types of analysis performed in this study included both logistical and linear 
regression modeling. These modeling strategies allow for controlling of known PC risk 
factors and other independent variables, thereby providing a linear combination of 
optimally weighted independent variables that best explain the outcome variable. 
5.5 - External Validity 
The study’s subjects were men treated within the VA Healthcare networks located 
in Tampa, Florida. The demographic characteristics of the population under study are 
similar to that of the national VA system. The group are primarily Caucasian middle-aged 
veterans (mean=68 y/o, SD=12) with an education attainment level of at least four years 
of high school, or some college attendance.36     
Approximately 2.5 million individuals receive all or part of their healthcare needs 
from the VA medical system, and the Tampa Florida VA healthcare network handles on 
average a total of 1,718,528 male patient encounters each year.36 Given the above, this 
study’s subjects are believed to be representative of the national male VA population. 
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5.6 - Public Health Importance and Future Directions   
Men with PC have been described as falling in to one of four groups, and 
screening can only benefit one of the groups. The first group consists of men with 
normally progressing disease that is identified clinically; the second group includes men 
with PC that advances very rapidly. For the above two groups, screening is of no benefit. 
The third groups contains men with screen-detected PC that would have never advanced 
to clinically relevant disease, therefore they are exposed to unnecessary procedures and 
treatments. Lastly, group four contains asymptomatic men who have PC identified 
through screening and receive beneficial outcomes that otherwise would have been 
deprived if not for the screening.10 One difficulty in PC screening is identifying group 4 
relative to group 3. This study results suggest evaluating four laboratory biomarkers 
(HGB, RBC count, MCV, creatinine) in conjunction to a PSA value of >4ng/dL might 
increase the validity of the PC screening process. This has important implications, 
especially if PSA is used as a cost effective PC screening program. The overlap of PSA 
values in men with PC and non-cancerous prostate conditions has been well documented. 
This study provides a glimpse of the potential benefit that these additional lab parameters 
can provide. 
Future directions should first begin with repeating this study on multiple VA data 
sets collected from different VA clinics around the U.S. Are the findings similar in data 
sets that originate from a different geographic location? Do they vary in VA data sets that 
are from communities with different age distributions, or in areas with higher proportions 
of African American men? Individuals considered at high risk for PC include men with a 
positive family history; advancing age, and African-Americans.10, 106 Does this clinical 
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decision rule perform better for these high risk subsets? Can it address previous 
descriptive epidemiology that describes PC as affecting African-American men in more 
aggressive nature, and at an earlier age? Moreover, capturing information on PC family 
history is of paramount importance. Would the employment of this clinical decision rule 
result in a significant decrease of prostate biopsy numbers without increasing the false 
negatives? Does the duration of disease affect the degree of change for each biomarker, 
and by how much?  
Stratification analysis techniques can provide additional insight on high risk 
patients and exposures, and although this study contained large numbers of patients with 
PC and non-cancerous prostate conditions (N=1,378), future studies should include a 
larger sample size, given that it will facilitate further stratification. Only after replicating 
this study on different data sets (and demonstrating consistency of findings), should a 
randomized prospective study be considered.  
 Perhaps the most important question yet to be answered is this: Given an elevated 
PSA value and values of the specified laboratory biomarkers that yield a probability 
value above the cut-off point, would a clinician confidently recommend a prostate biopsy 
for his/her patient? Moreover, if there is a lack of change in the biomarkers, would a 
clinician confidently recommend a more conservative, expectant observation (watchful 
waiting) approach?   
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Appendix:  
The following case examples provide a glimpse of the real world application of 
the proposed clinical decision rule outlined in this study. 
Case example 1: (For this example, method 1, cut-point 1 will be utilized) 
The probability of this cut-point is .45, therefore the Log OR p/1 – p = .45/1-.45, thus the 
cut-point is -0.08. (If the number yielded from equation is above this value, the patient 
should be referred for prostate biopsy). The patient is a 67 year old, African American 
male with a recent PSA test value of 5.2 (ng/dL). Additional lab work: HGB 10.5, RBC 
count 4.45, MCV 94.1, Albumin 4.0, Creatinine 1.12, and a positive test for Hematuria 
(at least 1 RBC per high powered field)     
Prob..45/.55=     
-0.08 (cut-
point)  Patients value Parameter estimate 
Pt. value 
*Parameter 
estimate Intercept 
HGB 10.5 -0.3519 -3.69 -7.95 
RBC 4.45 0.9227 3.65   
Black (Yes=1) 1 0.6336 0.63   
Hematuria (Yes=1) 1 -0.2874 -0.29   
Age 67 0.0196 1.31   
Albumin 4 0.2871 1.15   
PSA 5.2 0.0408 0.21   
Creatinine 1.12 -0.4393 -0.49   
MCV 94.10 0.0663 6.05   
    sum of B*value 8.53   
    
plus intercept= Total 
Score .58   
Patients CDR Total Score 0.58 > -0.08. Recommendation? Send for Biopsy 
Figure 12. Case Example 1 using Method 1, cut-point 1 
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Case example 2: (For this example, method 2, cut-point 1 will be utilized) 
The probability of this cut-point is .41 therefore the Log OR p/1 – p = .41/.59, thus the 
cut-point is -0.16 (If the number yielded from equation is above this value, the patient 
should be referred for prostate biopsy). The patient is a 75 year old, Caucasian male with 
a recent PSA test value of 4.3 (ng/dL). In addition, he had additional lab work to include 
a HGB, RBC count, MCV, and Creatinine:  
Prob..41/1-.41 
=     -0.16  Patients value Parameter estimate 
Pt. value 
*Parameter 
estimate Intercept 
HGB 15.2 -0.378 -5.74 -5.10 
RBC 4.50 0.764 3.44   
Black (Yes=1) 0 0.361 0.00   
Age 75 0.018 1.35   
PSA 4.3 0.033 0.129   
Creatinine 1.65 -0.601 -0.99   
MCV 90.00 0.050 4.5   
    sum of B*value 2.69   
    
plus intercept= Total 
Score -2.41   
 Patients CDR Total Score -2.41< -0.16. Recommendation? No Biopsy 
Figure 13. Case Example 2 using Method 2, cut-point 1 
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Case example 3: (For this example, method 3, cut-point 1 will be utilized) 
The probability of this cut-point is .45, therefore the Log OR p/1 – p = .45/1-.45, thus the 
cut-point is 123456. (If the number yielded from equation is above this value, the patient 
should be referred for prostate biopsy). The patient is a 87 year old, African American 
male with a recent PSA test value of 14.7 (ng/dL). In addition, he had additional lab work 
to include a HGB, RBC count, MCV, and Creatinine.   
Prob..42/1-.42 
=     -0.14  Patients value Parameter estimate 
Pt. value 
*Parameter 
estimate Intercept 
HGB 11.2 -0.472 -5.29 -6.80 
RBC 4.12 1.105 4.55   
Black (Yes=1) 1 0.609 0.61   
Age 87 0.024 2.09   
PSA 14.7 0.054 0.79   
Creatinine 0.98 -0.815 -0.80   
MCV 89.51 0.066 5.91   
    sum of B*value 7.86   
    
plus intercept= Total 
Score 1.06   
Patients CDR Total Score 1.06 > -0.14. Recommendation? Send for Biopsy 
Figure 14. Case Example 3 using Method 3, cut-point 1 
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 All 
Ethnicity 
White African- 
American 
Hispanic Other Unknown/Refused Totals 
Prostate 
Cancer 
616 
44.7% 
428 
43.9% 
67 
57.3% 
28 
39.4% 
15 
33.3% 
78         
45.9% 
616 
     Stage A (332) 
53.9% 
(238) 
55.6% 
 (34) 
50.7% 
  (15) 
53.6% 
  (11) 
73.3% 
 (34)     
43.6% 
332 
    Stage B (220) 
35.7% 
(149) 
34.81% 
 (22) 
32.8% 
  (11) 
39.3% 
   (3) 
20.0% 
 (35)     
44.9% 
220 
    Stage C   (48) 
7.80% 
  (31) 
7.24% 
   (7) 
10.4% 
   (1) 
3.5% 
   (1) 
6.66% 
  (8)      
10.2% 
  48 
   Stage D   (16) 
2.59% 
  (10) 
2.34% 
   (4) 
6.00% 
   (1)       
3.5% 
   (0) 
0.00% 
 (1)                  
1.3% 
  16 
PIN 138 
10.0% 
99 
10.15% 
13 
11.1% 
7   
9.86% 
6 
13.3% 
13         
7.65% 
138 
BPH 282 
20.5% 
211 
21.6% 
19 
16.24% 
14 
19.7% 
10 
22.2% 
28         
16.5% 
282 
Prostatitis 342 
25.0% 
237 
24.3% 
 18 
15.4% 
22 
31.0% 
14 
31.1% 
51         
30.0% 
342 
Total 
prostate 
biopsies 
1,378 975 117 71 45 170 N=1,378
Table 22: Baseline data by Ethnicity/Histologic biopsy. 
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